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ABSTRACT
Treatment Effect Estimation for Randomized Clinical Trials Subject to
Noncompliance and Missing Outcomes
by
Shan Kang
Chair: Roderick Little and Thomas Braun
Noncompliance and missing outcomes are common in randomized clinical trials. In
this dissertation, we explore treatment arm switching issues for survival data and
nonrandom dropout issues for masked clinical trials.
In Chapter 2, we consider noncompliance in phase III clinical trials in oncolo-
gy. Although patients are randomized to their treatment assignments, the option of
treatment switching may be offered to patients who experience disease recurrence for
ethical considerations. Standard statistical methods that ignore this nonrandom non-
compliance can lead to biased estimations. Although methods do exist to account for
the effect of treatment arm switching, several of these methods focus on quantifying
an overall switching effect, which can still lead to biased results if the benefit derived
from switching varies among patients. We propose a new parametric method to ad-
dress this limitation that factorizes the likelihood into two parts in order to evaluate
the individual benefit of switching. A more robust latent event time approach is also
proposed for the possible assumption violation. In simulation studies, our proposed
methods outperform the existing methods.
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In Chapter 3, we consider missing outcome problems in masked (blinded) clinical
trials. Most standard models for analyzing the data make the missing at random
(MAR) assumption, but in practice, there are often situations where missingness
is likely to depend on the outcome, so MAR is not valid. For masked trials, we
propose a specific missing not at random (MNAR) assumption, which we call masked
MNAR (MMNAR): since the specific treatment received is unknown, masking justifies
the assumption that missingness does not depend on treatment assignment after
conditioning on outcomes and side effects. We suggest that methods based on the
MMNAR assumption are useful for masked clinical trials, either in their own right
or to provide a form of sensitivity analysis for deviations from MAR. We formulate
models for categorical and continuous outcomes under this assumption. Simulations
show that our proposed methods outperform other methods when MAR is violated
and the efficiency of treatment effect estimates is similar to that of MAR methods
when MAR is true. We apply our methods to the TRial Of Preventing HYpertension
(TROPHY) study (Julius et al., 2006).
In Chapter 4, we develop regression-based multiple imputation models that exploit
the MMNAR assumption proposed in Chapter 3 for longitudinal data. Simulation
studies are conducted to compare the performance of the proposed method with other
methods. The idea is also illustrated with the TROPHY study.
viii
CHAPTER I
Introduction
Randomized controlled trials (RCTs) are the gold standard for investigating the
effectiveness of a medical intervention, because the randomization of patients to the
experimental treatment arm or comparative control protects the comparison between
two arms from selection bias and confounders of treatment effect. For an ideal clinical
experiment, after participants are randomly assigned to treatment arms, they actually
receive the interventions exactly as specified in the protocols, and provide measures
of outcome. In this case, randomization, complete compliance, and no loss of follow
up enable us to draw valid statistical inferences for the treatment effect. In this
cases, the ‘double blind’ experiments are preferred, because this approach conceals
the treatment assignment from the subject and the clinician to prevent the potential
bias caused by knowing this information.
In practice, such conditions are difficult to achieve because of a variety of hu-
man behaviors. As a result, missing data are common in many clinical trials. For
example, subjects may (partially) fail to take their assigned treatments, or receive
an alternative treatment as a rescue therapy. This treatment discontinuation can be
conceptualized as a form of noncompliance (Rubin, 1987) and must be accounted for
properly. When participants discontinue their assigned treatment, their outcomes
can still be recorded, and those who remain on their assigned treatment can have
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missing outcomes. For example, when subjects miss their clinic visits, outcomes are
not recorded but they still receive assigned treatment. Or the study is terminated for
administrative reasons, all outcomes are missing but there is no evidence to show that
the participants would discontinue their treatment if the study was still going on. It
is important to distinguish between treatment discontinuation and missing outcomes
(Meinert, 1980), although they often appear together, as when the subjects are lost
to follow-up, the underlying reason could be noncompliance and the outcomes are
missing.
There are many possible reasons for noncompliance, but as they are often not
random, the benefits of randomization are undermined. The most widely accepted
approach to handle noncompliance is the ‘intention-to-treat’ (ITT) analysis. In ITT
analysis, all randomized patients are analyzed according to the treatment they were
originally assigned, regardless of the actual treatment received or subsequent with-
drawal from treatment (Hill, 1961). In ITT analysis, the entire treatment regimen
including treatment discontinuation is evaluated as a whole. This approach tends to
estimate a diluted treatment effect, sometimes called treatment effectiveness, which is
generally a conservative estimate comparing with treatment efficacy, the effectiveness
of a treatment when it is in fact taken (Little et al., 2009).
An alternative to ITT analysis is ‘per-protocol’ (PP) analysis, in which only the
patients who comply with the assigned treatment are counted towards the final result.
In PP analysis, the treatment efficacy is estimated. However, with this approach,
selection bias may be a problem, because people who experience better outcomes are
more likely to remain in the data set, and PP analysis may provide overoptimistic
estimates of the efficacy of the treatment resulting from the removal of non-compliers.
Several existing methods for analyzing complete data sets are briefly reviewed
here. Most of the missing data approaches introduced below are based on them.
Maximum likelihood (ML) methods maximize the likelihood function, which is based
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on the specified joint density function for all observations. ML has many good prop-
erties including consistency, asymptotic normality, functional invariance, asymptotic
efficiency, and many others under some regularity conditions. Bayesian inference
method is another approach. This approach uses Bayes’ rule to update the probabili-
ty estimate when additional evidence is acquired. For longitudinal data, mixed effect
models can be used to introduce correlation between observations. Another approach
is to specify the variance covariance matrix directly. Generalized estimating equa-
tions (GEE) (Liang and Zeger, 1986) are also popular in estimating the parameters
of a model with a possible unknown correlation between outcomes, which is because
parameter estimates from the GEE are consistent even when the covariance structure
is misspecified.
When outcomes are missing, one common approach is complete case (CC) anal-
ysis, in which only subjects who have all variables observed are used. CC analysis
results are unbiased when the missingness is independent of both observed and un-
observed variables, which is called missing completely at random (MCAR). Although
CC analysis is the default option in many statistical software, it is criticized because
MCAR is generally unrealistic and even if MCAR is assumed, it discards the infor-
mation in the incomplete cases. CC analysis is also valid when the missingness does
not depend on outcomes in a regression, in which no distribution assumption is made
for the covariates.
Alternative missing data adjustment methods often assume that the missing data
are missing at random (MAR), in the sense that missingness does not depend on
the missing values after conditioning on the observed data (Rubin, 1976). Approach-
es based on MAR include ignorable likelihood-based methods such as parametric
multiple imputation (MI) (Rubin, 1987) and maximum likelihood (ML) estimation,
and inverse probability-weighted methods (Robins et al., 1995). Ignorable likelihood-
based methods have the advantage of retaining all the data, and are fully efficient
3
as long as MAR is true. Furthermore, they are robust, performing reasonably well
even when the MAR assumption is slightly violated (Little and Zhang, 2011). The
robustness is because the efficiency gain by using more cases outweighs the bias result-
ing from incorrectly ignoring the missing data mechanism. In multiple imputation,
missing values are replaced by D (=5 or 10) imputed versions. For inference, each of
the imputed complete data sets is analyzed by standard methods, and those results
are combined to calculate estimates and confidence intervals which can incorporate
uncertainty from missing data.
When data on outcomes are missing because of adverse events or lack of treat-
ment efficacy, missingness depends on the missing values and the MAR assumption
is violated. Such mechanisms are called missing not at random (MNAR), or non-
ignorable (Rubin, 1976; Little and Rubin, 2002). Joint models for the outcomes and
missing indicators are usually required for non-ignorable missing data mechanisms.
Little (1993) considered two classes of joint models: selection models and pattern-
mixture models. Selection models factorize the joint model of outcomes and missing
indicators into a model for the marginal outcomes and another model of missing in-
dicators conditional on the possibly unobserved outcomes. Pattern-mixture models
factorize the joint model into a model of missing data patterns and another model for
outcomes given missing data patterns. In either approach, unverifiable restrictions or
assumptions are required to identify the parameters (Fitzmaurice et al., 2005). Re-
searchers have proposed sensitivity analyses to address this issue (Little and Rubin,
2002; Scharfstein et al., 1999; National Research Council, 2010), but in practice only
a limited set of MNAR models can be assessed.
In this dissertation, we explore two missing data problems in clinical trials: treat-
ment arm switching issues for survival data and nonrandom dropout issues for masked
clinical trials.
In Chapter 2, we consider noncompliance problem in phase III clinical trials in
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oncology, which evaluate the survival benefit for a new treatment relative to an exist-
ing treatment or standard-of-care. Although patients are randomized to their treat-
ment assignments, ethical motivations dictate that patients who experience disease
recurrence or other event indicating increased likelihood of death may be offered the
option to switch to the other treatment arm and continue to be followed for survival.
Standard statistical methods that ignore this non-random noncompliance can lead to
biased estimation of the survival benefit attributed to the new treatment. Although
methods do exist to account for the effect of treatment arm switching, several of these
methods focus on quantifying an overall switching effect, which can still lead to biased
results if the benefit derived from switching varies among patients.
We propose a new parametric method to address this limitation that factorizes
the likelihood into two parts in order to evaluate the individual benefit of switching.
For the cases when assumptions in the above parametric method may be violated,
we propose another more robust latent time method inspired by iterative parameter
estimation (IPE) procedure (Branson and Whitehead, 2002). Via simulation, we ex-
amine the performance of our methods and compare the performance with existing
methods including (1) ITT analysis; (2) PP analysis in which patients who switch
treatment arms are either omitted entirely from analysis or are treated in the anal-
ysis as censored at the time of switching; (3) Cox proportional hazards model (PH)
with treatment arm as a time-varying covariate; (4) IPE procedure which assumes
a parametric accelerated failure-time (AFT) model with a multiplicative treatment
effect of exp(η), and iteratively calculate the value of ηˆ and latent event times until
values for ηˆ converge.
In Chapter 3, we consider missing outcome problems in masked (blinded) clinical
trials. Most standard models for analyzing the data make the MAR assumption,
but in practice, there are often situations where missingness is likely to depend on
the outcome, so MAR is not valid. For masked trials, we propose a specific MNAR
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assumption, which we call masked MNAR (MMNAR): since the specific treatment
received is unknown, masking justifies the assumption that missingness does not de-
pend on treatment assignment after conditioning on outcomes and side effects. We
suggest that methods based on the MMNAR assumption are useful for masked clin-
ical trials, either in their own right or to provide a form of sensitivity analysis for
deviations from MAR. MAR analysis might be favored on grounds of efficiency if the
estimates based on MMNAR and MAR are similar, but if the estimates are substan-
tially different, the MMNAR estimates might be preferred because the mechanism is
more plausible. We formulate models for categorical and continuous outcomes under
this assumption. Simulations are conducted to examine the finite sample performance
of ML methods assuming MMNAR and compare them with other methods such as
CC analysis and ML assuming MAR. We also applied our methods to the TRial Of
Preventing HYpertension (TROPHY) study (Julius et al., 2006).
In Chapter 4, we further extend the MMNAR assumption proposed in Chapter 3
to longitudinal data models. Since there are many possible longitudinal models, we
propose a strategy to develop a longitudinal MMNAR model based on the preferred
longitudinal model for complete data. The estimation procedure including a regres-
sion step and an imputation step is also presented. Simulation studies are conducted
to compare the performance of the proposed method with other methods. The idea
is also illustrated with the TROPHY study.
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CHAPTER II
Estimating Survival Benefit in Randomized
Clinical Trials with Treatment Arm Switching
After Disease Progression
2.1 Introduction
Randomized controlled trials (RCTs) are often considered the gold standard for
evaluating the efficacy of an experimental treatment, as the randomization of patients
to the treatment arm or the comparative control arm limits the impact of selection
bias and possible confounding of the potential treatment effect. After randomization,
each patient is followed for a pre-specified period of time, often several years, during
which the occurrence of a primary event of interest, usually death from any cause,
may occur. Patients who do not die before the end of their follow-up are considered
censored for death, necessitating the use of censored data methods, i.e. log-rank tests
and Cox regression, to compare the difference between the overall survival (OS) rates
of the treatment arms.
In many diseases, such as cancer and acquired immune deficiency syndrome (AID-
S), death may be preceded by a serious event, such as recurrence of disease with cancer
or continued elevation of CD34+ cells with AIDS, that is associated with death and
would suggest that the treatment assignment of the patient be switched for compas-
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sionate and ethical reasons. For example, Slamon et al. (2001) described an RCT
comparing the use of standard chemotherapy (anthracycline plus cyclophosphmide
or paclitaxel) alone or in combination with the recombinant monoclonal antibody
trastuzimab (Herceptin) for the treatment of metastatic breast cancer. At the time
of disease progression, all patients had the option of enrolling in a follow-up (non-
randomized) study of Herceptin alone or in combination with chemotherapy in hopes
of prolonging overall survival. Of the 234 patients randomized to chemotherapy alone,
66% elected to receive Herceptin as part of this follow-up study. The combination
of the data from the the RCT and the follow-up study were then used to assess the
effect of Herceptin on overall survival (Lewis et al., 2002).
A second example is the RECORD-1 trial, which studied everolimus, which al-
ters the mammalian target of rapamyacin (mTOR) pathway, a known pathway of
the pathogenesis of renal cell carcinoma (RCC) (Motzer et al., 2008). RECORD-1
enrolled 416 patients with metastatic RCC, each of whom was randomized to re-
ceive either everolimus plus best standard of care (BSC) or placebo plus BSC. The
primary endpoint was progression-free survival (PFS), which is the earlier of disease-
progression or death, because the treatment assignment of patients with disease pro-
gression were unblinded, and those randomized to placebo plus BSC were allowed to
switch to everolimus plus BSC at the time of disease progression. However, the pub-
lished PFS results were accompanied by an editorial that questioned the use of PFS
as an endpoint for RCC (Knox, 2008), a concern that has now pervaded through the
design of RCTs in cancer treatment, with most RCTs now using OS as the primary
endpoint. In response to the editorial, the OS results of the RECORD-1 trial, based
upon the rank-preserving structural failure time model of Robins and Tsiatis (1991)
were published later (Motzer et al., 2010). Other examples of treatment switching
and the resulting statistical issues include the use of sunitinib for the treatment of
gastrointestinal stromal tumors (Blay, 2010), the study of ganitumab in the treatment
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of breast cancer (Robertson et al., 2013), and the study of zidovudine in patients with
HIV infection (Concorde Coordinating Committee, 1994; White et al., 1999; Hernan
et al., 2000).
It is obvious that when OS is the primary endpoint for a RCT that allows pa-
tients to switch from their randomized assignments, comparison of the two arms will
be biased unless the switching is accounted for properly. When using standard sta-
tistical methods to estimate the difference in OS between the two arms, the simplest
and most-commonly used approach is an intent-to-treat (ITT) analysis, whereby the
follow-up of each patient is assigned completely to their original arm assignment, re-
gardless if they later switched to the other arm. However, if the treatment is truly
effective, then an ITT analysis will only serve to give a diluted treatment effect es-
timate. Furthermore, ITT produces an estimate of the effect of the entire treatment
regimen that includes switching, whereas usually investigators are interested solely in
the effect in the treatment when switching is not an option in practice, a parameter
referred to as “biological efficacy” by Sommer and Zeger (2011).
Another method is termed a “per-protocol” approach, in which patients who
switch treatment arms are either omitted entirely from analysis or are treated in
the analysis as censored at the time of switching. Neither of these approaches is sat-
isfactory, as both approaches fail to use all information available in the data, thereby
reducing the power of the study. Moreover, both per-protocol approaches lead to a bi-
ased analysis of a selected subset of patients who are no longer balanced with respect
to all confounding factors. The bias is further compounded when the probability of
switching is related to disease progression, as it is in all the RCTs cited earlier. We
note that Law and Kaldor (1996) proposed a modified ITT analysis approach that
seems to have received little use in application, although it has been shown to lead
to valid estimation under a weaker set of restrictions than a crude ITT analysis. A
more detailed examination of the weaknesses of ITT and per-protocol approaches can
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be found in Morden et al. (2011).
Several statistical approaches have been developed that incorporate the complete
follow-up of all patients and give an unbiased estimate of treatment effect when certain
assumptions are met. As stated earlier, data from the RECORD-1 trial were analyzed
using the methods of Robins and Tsiatis (1991), which assume that treatment has a
multiplicative effect (eη; the model with η will be described later in detail) on each
patient’s overall survival. Each patient is assigned a latent event time that would
have been observed had no treatment been received, and a rank-based statistic, given
a value of η, is computed using the latent values. A grid search among a range of
possible values for η is used until one identifies the value that leads to a rank-based
statistic of zero; this value of η is the estimated treatment effect ηˆ. However, this grid
search can be computationally expensive, as no systematic or iterative process exists
for identifying ηˆ.
In response to this limitation, Branson and Whitehead (2002) proposed an itera-
tive parameter estimation (IPE) procedure. A parametric (e.g. Weibull or exponen-
tial) accelerated failure-time model is assumed with a multiplicative treatment effect
of eη, and ηˆ is computed from the data as randomized. Based upon this value of
ηˆ, latent event times are then formulated for patients who switched treatment and
these latent event times replace the corresponding observed event times in the data.
A updated value of ηˆ is then computed, from which one formulates updated latent
event times, and this iterative process continues until values for ηˆ converge. Thus, as
stated by White (2006), the methods of Robins and Tsiatis (1991) and Branson and
Whitehead (2002) assume the same estimand and differ only by whether a rank or
parametric test is used to determine ηˆ. However, White (2006) does emphasize that
the methods of Branson and Whitehead (2002) as published do not adequately deal
with censored subjects because they do not correctly recensor subjects as outlined by
White et al. (1999). Thus, in a study with a large amount of censoring, the value of
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ηˆ can be biased with IPE.
Shao et al. (2005) also extended the IPE procedure by proposing to use a Cox
regression model, rather than a fully parametric model, for survival times, and thereby
have a likelihood-based approach for estimating η which is computationally simpler
than the iterative approach of Branson and Whitehead (2002). Shao et al. (2005) also
introduce a weight function that allows for a differential treatment effect for patients
randomized initially to the treatment arm and patients randomized initially to control
and later switch to the treatment arm. Nonethless, White (2006) demonstrated that
these methods are based upon a likelihood that is conditional upon the switching
times and therefore can be biased when switching is not ignorable, i.e. is correlated
with prognosis. Most recently, Zheng et al. (2012) developed a computationally-
intensive method based on a semi-parametric hazards model. Instead of calculating
latent event times, Zheng et al. (2012) only model the observed event times and
instead use separate models for each of: (a) the time of the event causing a switch
to another arm, (b) the time from switching to death, and (c) the time of death for
those who did not switch from their original arm assignment.
We present a parametric approach as an alternative to the methods just discussed.
In Section 2.2, we propose our new parametric model and Section 2.3 contains the
details of parameter estimation. In Section 2.4, we examine the performance of our
methods via simulation. In Section 2.5, we compare the performance of our methods
to existing approaches and also present two approaches for limiting the bias of the IPE
algorithm applied to multivariate normal data. Concluding remarks are in Section
2.6.
2.2 Parametric Model
We have a clinical trial designed to assess the difference in overall survival between
patients receiving a control and patients receiving an experimental agent (treatment).
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Patients are initially randomized equally to either arm (j = 0 for control; j = 1 for
treatment) and each is followed until the earliest of (a) censoring, (b) progression of
disease, or (c) death. Patients on the control (treatment) arm with progression of
disease are allowed to switch to the treatment (control) arm at the time their disease
progresses. We let Xi, i = 1, 2, . . . n denote the arm to which patient i was assigned
and Yi denotes the arm assignment for patient i after disease progression in patients
whose disease progresses. We emphasize that disease progression does not imply a
patient will switch to the other arm with certainty, as some patients most likely will
remain on their original arm even after disease progression. To that end, Mij is the
binary indicator of whether or not subject i experienced disease progression after
randomization to arm j, and Rij denotes if patient i switched treatment, i.e Xi = j
and Xi 6= Yi. Thus, Mi,Xi is the observed indicator of progression for subject i, while
Mi,(1−Xi) is a latent indicator of progression for subject i had they been randomized
to the other arm. We let p1j = Prob(Mij = 1) and p0j = (1− p1j) = Prob(Mij = 0).
We let Ti0 and Gi0 be the respective time to progression and time to death after
progression in patients initially randomized to control, and TGi0 is the time from
randomization to death in patients randomized to control without disease progres-
sion. We have similar definitions of Ti1, Gi1, and TGi1 for patients randomized to the
treatment arm. Note that under this model, Gij, the time to death for patient i in
arm j after disease progression, is independent of the original treatment assignment
of patient i. Specifically, if patient i were originally assigned to the control arm and
did not switch to the treatment arm after disease progression, a period of time Gi0
would be observed for this patient. By our assumption, if that patient had instead
been assigned to the treatment arm and switched to the control arm after progres-
sion, the same length of time Gi0 would be observed after progression. Last, we let
Ci denote the censoring time for patient i. We further assume that the decision of
treatment switching is independent of the potential outcomes Gi0 and Gi1 given the
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progression time Tij, and the censoring time is also assumed to be independent of
each of Tij, Gij, and TGij. In summary, the observed data for each patient are one
of twelve possibilities outlined in Table 2.1.
Table 2.1: Summary of the data to be observed in the clinical trial, dependent upon
disease progression, treatment arm switching, and censoring.
Initial Arm Censored Progression Switch Observed Data for Patient i
Control no no n/a Xi = 0, Mi0 = 0, TGi0
yes no Xi = 0, Mi0 = 1, Ri0 = 0, Ti0, Gi0
yes yes Xi = 0, Mi0 = 1, Ri0 = 1, Ti0, Gi1
Treatment no no n/a Xi = 1, Mi1 = 0, TGi1
yes no Xi = 1, Mi1 = 1, Ri1 = 0, Ti1, Gi1
yes yes Xi = 1, Mi1 = 1, Ri1 = 1, Ti1, Gi0
Control yes no n/a Xi = 0, Ci
yes no Xi = 0, Mi0 = 1, Ri0 = 0, Ti0, Ci
yes yes Xi = 0, Mi0 = 1, Ri0 = 1, Ti0, Ci
Treatment yes no n/a Xi = 1, Ci
yes no Xi = 1, Mi1 = 1, Ri1 = 0, Ti1, Ci
yes yes Xi = 1, Mi1 = 1, Ri1 = 1, Ti1, Ci
Thus, in the absence of censoring, we have a total of six duration of times for
subject i: Ti0, Gi0, TGi0, Ti1, Gi1, and TGi1, some of which are observed and some of
which are latent depending on the original arm assignment and whether or not disease
progression occurs. We will directly model the joint distribution of Ti0, Gi0, TGi0, and
Ti1, and then make assumptions that allow us to determine distributions for Gi1 and
TGi1. Specifically, the vector (log Ti0, log Ti1, log Gi0, log TGi0) has a multivariate
normal distribution with mean vector (µ0, µ1, µ2, µ0E) and covariance matrix

σ20 ρ1σ0σ1 ρ2σ0σ2 ρ4σ0σ0E
ρ1σ0σ1 σ
2
1 ρ3σ1σ2 ρ5σ1σ0E
ρ2σ0σ2 ρ3σ1σ2 σ
2
2 ρ6σ2σ0E
ρ4σ0σ0E ρ5σ1σ0E ρ6σ2σ0E σ
2
0E

(2.1)
13
We define DT i = log Ti1−log Ti0, which is also normally distributed and has mean
∆ = µ1 − µ0 and variance σ2D = σ21 + σ20 − 2ρ1σ0σ1. The parameter ∆ quantifies the
treatment effect of interest, and, as defined, holds only for the time before progression
in patients with disease progression. We therefore assume that this treatment effect
carries over to the time from progression to death, as well as the time to death in
patients who do not experience disease progression. Specifically, we assume that
DGi = log Gi1 − log Gi0 and DTGi = log TGi1 − log TGi0 are both equal to DT i, i.e.
DT i ≡ DGi ≡ DTGi, and this assumption leads to distributions for Gi1 and TGi1 and
establishes a fully parametric model.
Although our assumption that the treatment effect is the same both before and
after disease progression may seem strong, it actually leads to intuitive results. In
patients randomized to control who experience disease progression, we would expect
that the effect of the treatment in these patients would be related to when their disease
progressed. Specifically, the benefit of the treatment is expected to be greater in those
whose disease progressed earlier than average as compared to those whose disease
progressed later than average, a concept referred to by White (2006) as “individual
benefit to be gained from treatment,” which we denote as Bi.
This concept can be explained by our proposed model. If patient i is assigned to
the control arm and experiences disease progression at time ti0, the expected condi-
tional treatment effect after progression is
E(logGi1 − logGi0| log Ti0 = log ti0) = E(log Ti1 − log Ti0| log Ti0 = log ti0)
= E(log Ti1| log Ti0 = log ti0)− log ti0
= µ1 + ρ1σ0/σ1(log ti0 − µ0)− log ti0
= µ1 − µ0 + ρ1σ0/σ1(log ti0 − µ0)− log ti0 + µ0
= ∆ + (ρ1σ0/σ1 − 1)(log ti0 − µ0)
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with Bi = (ρ1σ0/σ1 − 1)(log ti0 − µ0). Since we expect σ0 and σ1 to be relatively
similar to each other and ρ will not be large enough to dominate the ratio of σ0 and
σ1, it is very likely in practice that (ρ1σ0/σ1− 1) < 0. Thus, Bi > 0 when log ti0 < µ0
and Bi < 0 when log ti0 > µ0, meaning that the individual treatment benefit from
switching is large for patients with early progression relative to patients with average
time to progression. In fact, our model presumes that those who progress later than
average will receive less benefit from switching to the treatment arm than those with
average time to progression. Therefore, the concept of a positive benefit attributed to
switching is supported by our model independent of the sign of µ1−µ0, and switching
a patient’s treatment arm assignment based on their observed time to progression is
justified.
We note that our methods define the treatment effect as ∆ = E{log(Ti1/Ti0)},
so that e∆ ≈ E{Ti1/Ti0}. We contrast this definition of treatment effect with the
following two alternatives
∆∗ = log
(
E[Mi1(Ti1 +Gi1)] + E[(1−Mi1)TGi1]
E[Mi0(Ti0 +Gi0)] + E[(1−Mi0)TGi0]
)
(2.2)
∆∗∗ = E
[
log
(
Mi1(Ti1 +Gi1) + (1−Mi1)TGi1
Mi0(Ti0 +Gi0) + (1−Mi0)TGi0
)]
(2.3)
Although ∆,∆∗, and ∆∗∗ are not identical quantities, it can be shown that
∆ = ∆∗∗ if either p10 = p11, i.e. the probability of progression is the same in both
arms, or Ti0 + Gi0 = TGi0, i.e. the sum of the time to progression and time from
progression to death for a patient with progression is the same as the time to death
for a patient without progression. However, both of these equalities have little bi-
ological justification. Although ∆∗∗ is related more closely to ∆, ∆∗ is the most
commonly defined treatment effect because it can be directly obtained from the data
in the absence of treatment switching and censoring. In Section 2.4, estimates of ∆,
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∆∗, and ∆∗∗ will all be presented as summaries of the performance of our proposed
method and estimates of ∆∗ will be presented when comparing our proposed methods
to existing methods.
2.3 Likelihood and Parameter Estimation
Since we have a fully parametric model, we can use maximum-likelihood meth-
ods to estimate parameters, although some of the parameters are not estimable and
will be discussed in further detail. As outlined in Table 2.1, the contribution of
each subject to the likelihood is a function of their original treatment assignmen-
t, whether or not they experience disease progression, whether they switch treat-
ment arms after disease progression, and when they are censored. We let θ =
{p10, p11, µ0, µ1, µ2, µ0E, σ20, σ21, σ22, σ20E, σ21E, ρ1, ρ2, ρ3} be the vector of the 14 parame-
ters to be estimated. The parameter σ21E will be described in the outline below, and is
used in the likelihood in place of ρ4, ρ5, and ρ6, which are not estimable from the data.
We let Ki = 1, 2, . . . 12 be the indicator as to which of the twelve possibilities subject
i resides and their corresponding likelihood contribution to be LKi , leading to a joint
likelihood function
∏n
i=1 LKi . We now outline the twelve possible likelihood contribu-
tions of each subject in more specific terms. In the following outline, φ(x | µ, σ2) and
Φ(x | µ, σ2) denote the density and cumulative probability function, respectively, of
a normal distribution with mean µ and variance σ2. We also organize our outline by
first describing the six possibilities when patients are not censored, which are then
followed by the corresponding possibilities when patients are censored.
• Ki = 1: patient i is assigned to the control arm and does not experience disease
progression. We observe their time to death TGi0 and L1 = φ(log TGi0 | µ0E, σ20E);
• Ki = 2: patient i is assigned to the control arm, experiences disease progression,
and does not switch to the treatment arm. We observe their time to disease
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progression, Ti0, and their time from disease progression to death, Gi0. Since
(Ti0, Gi0) is not a random sample, their likelihood contribution cannot be based
upon their joint distribution. Instead, we use the product of the conditional dis-
tribution of Gi0 given Ti0 and the marginal distribution of Ti0. Since logGi0 giv-
en Ti0 = ti0 has a normal distribution with mean µ˜i2 = µ2+(ρ2σ2/σ0)(log ti0−µ0)
and variance σ˜22 = σ
2
2(1−ρ22), we have L2 = φ(log Ti0 | µ0, σ20)φ(logGi0 | µ˜i2, σ˜22);
• Ki = 3: patient i is assigned to the control arm, experiences disease progression,
and switches to the treatment arm. We observe their time to disease progression,
Ti0, and time from disease progression to death, Gi1. Through our assumption
that logGi1− logGi0 = log Ti1− log Ti0, we can derive the mean and variance of
Gi1 conditional on Ti0 = ti0, whose respective values are µ˜i3 = µ1 +µ2− log ti0 +
(ρ1σ1/σ0+ρ2σ2/σ0)(log ti0−µ0) and σ˜23 = σ21(1−ρ21)+σ22(1−ρ22)+2σ1σ2(ρ3−ρ1ρ2).
Thus, L3 = φ(log Ti0 | µ0, σ20)φ(logGi0 | µ˜i3, σ˜23);
• Ki = 4: patient i is assigned to the treatment arm and does not experience
disease progression. We observe their time to death, log TGi1 and from our as-
sumption that log TGi1− log TGi0 = log Ti1− log Ti0, we know that log TGi1 has
a normal distribution whose variance is a function of the inestimable parameters
ρ4, ρ5, and ρ6. Thus, we introduce σ
2
1E to denote the variance of log TGi1 and
use this parameter directly in the likelihood. Thus, L4 = φ(log TGi1 | µ˜4, σ21E),
in which µ˜4 = µ0E − µ0 + µ1.
• Ki = 5: patient i is assigned to the treatment arm, experiences progression,
and does not switch to the control arm. We observe their time to disease pro-
gression, Ti1, and time from disease progression to death, Gi1. Analogous to
the likelihood when Ki = 3, we first derive the conditional mean and vari-
ance of logGi1|Ti1 = ti1, which are µ˜i5 = µ2 − µ0 + log ti1 + (ρ3σ2/σ1 −
ρ1σ0/σ1)(log ti1 − µ1) and σ˜25 = σ20(1 − ρ21) + σ22(1 − ρ23) − 2σ0σ2(ρ2 − ρ1ρ3).
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Thus, L5 = φ(log Ti1 | µ1, σ21)φ(logGi1 | µ˜5, σ˜25).
• Ki = 6: patient i is assigned to the treatment arm, experiences progression,
and switches to the control arm. We observe their time to progression, Ti1, and
time from disease progression to death, Gi0. Analogous the likelihood when
Ki = 2, we see that logGi0|Ti1 = t1 has a normal distribution with mean
of µ˜i6 = µ2 + (ρ3σ2/σ1)(log ti1 − µ1) and variance σ˜26 = σ22(1 − ρ23). Thus,
L6 = φ(log Ti1 | µ1, σ21)φ(logGi0 | µ˜i6, σ˜26).
• Ki = 7: patient i is assigned to the control arm and is censored before ei-
ther progression or death occurs. We observe their time of censoring, Ci, and
the likelihood contribution is a mixture of patients who would have otherwise
died in the absence of disease progression and patients who would have other-
wise experienced disease progression prior to death. Thus, L7 = (1 − p10)[1 −
Φ(logCi | µ0E, σ20E)] + p10[1− Φ(logCi | µ0, σ20)].
• Ki = 8: patient i is assigned to the control arm, does not switch arms at
time of disease progression, and is censored before death. We observe their
time to disease progression, Ti0, and time from disease progression to censoring,
Ui = Ci − Ti0. Thus, L8 = φ(log Ti0 | µ0, σ20)[1− Φ(logUi | µ˜2, σ˜22)].
• Ki = 9: patient i is assigned to the control arm, switches arm at time of disease
progression, and is censored before death. We observe their time to disease
progression, Ti0, and time from disease progression to censoring, Ui = Ci − Ti0.
Thus, L9 = φ(log Ti0 | µ0, σ20)[1− Φ(logUi | µ˜3, σ˜23)].
• Ki = 10: patient i is assigned to the treatment arm and is censored before
either disease progression or death occurs. We observe their time of censor-
ing, Ci. Analogous to the likelihood when Ki = 7, we have L10 = p11[1 −
Φ(logCi | µ1, σ21)] + (1− p11)[1− Φ(logCi | µ˜4, σ21E)].
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• Ki = 11: patient i is assigned to the treatment arm, does not switch arms
at time of disease progression, and is censored before death. We observe their
time to disease progression Ti1, and time from disease progression to censoring
Ui = Ci − Ti1. Thus, L11 = φ(log Ti1 | µ1, σ21)[1− Φ(logUi | µ˜5, σ˜25)].
• Ki = 12: patient i is assigned to the treatment arm, switches arms at time
of disease progression, and is censored before dead. We observe their time to
disease progression, Ti1, and time from disease progression to censoring, Ui =
Ci − Ti1. Thus, L12 = φ(log Ti1 | µ1, σ21)[1− Φ(logUi | µ˜6, σ˜26)].
2.4 Simulation Studies
We examine the finite sample properties of our proposed methods via simulation.
We have a hypothetical clinical trial comparing an experimental agent and a control.
400 patients are randomized so that each arm has 200 patients. We first generate all
the possible event times (progression, death after progression, and death in absence of
progression) for each subject. We first draw the vector (log Ti0, log Ti1, log Gi0, log TGi0)
from a multivariate normal distribution with mean vector µ = (−1.3,−1.1,−1.2,−0.5)
and variance matrix with diagonal elements σ20 = 2.0, σ
2
1 = 1.8, σ
2
2 = 1.3, and σ
2
0E =
2.0 and off-diagonal elements such that ρ1 = 0.58, ρ2 = 0.50, ρ3 = 0.10, ρ4 = 0.40, ρ5 =
0.39, and ρ6 = 0.30. From the given values of log Ti0, log Ti1, logGi0, and log TGi0, we
compute logGi1 = logGi0 +log Ti1− log Ti0 and log TGi1 = log TGi0 +log Ti1− log Ti0.
We also draw independent censoring times Ci for each subject from a exponential dis-
tribution with mean 2. We then simulate a binary indicator of progression for each
subject using the probabilities p11 = 0.5 and p10 = 0.6. If a subject experiences pro-
gression, their data is comprised of either (i) their censoring time, (ii) their separate
times to disease progression and from disease progression to censoring, or (iii) their
separate times to disease progression and from disease progression to death. The data
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for subjects without disease progression are either (i) their censoring time or (ii) the
time to death.
Recall that when a patient has disease progression, it is possible for them to switch
to the arm to which they were not randomized if their expected individual benefit is
large enough to warrant switching. Thus, a rule must be formulated that determines
if a patient will switch arms at disease progression. We first examine the properties
of our methods when switching occurs if a patient has disease progression that occurs
earlier than the median progression time for their arm, which is exp(−1.1) = 0.33 for
the treatment arm and exp(−1.3) = 0.27 for the control arm. Since the actual median
may not be known and will have to be estimated, we will examine the properties of
our methods using a variety of decision rules.
Based upon the parameter values and switching rules stated above, the original
control arm consisted of 27% of patients who were censored before progression or
death, 12% of patients who were censored for death after progression (61% of whom
switched treatment arm), 26% of patients who died in the absence of disease progres-
sion, and 35% of patients whose death was observed after progression (60% of whom
switched treatment arm). The original treatment arm consisted of 33% of patients
who were censored before progression or death, 9% of patients who were censored
for death after progression (50% of whom switched treatment arms), 29% of patients
who died in the absence of disease progression, and 29% of patients whose death was
observed after progression (65% of whom switched treatment arms).
We use a Newton-Raphson algorithm to maximize the likelihood presented in
Section 2.3, with the marginal means and variances computed from the observed
data as initial parameter estimates. The data can also be used to generate a starting
value for ρ2. However, since ρ1 and ρ3 cannot be estimated, we use a starting value
of 0.15 for each. Theoretical expressions of the first and second derivatives are used
in the algorithm. The properties of our methods based on 1,000 simulations are
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presented in Table 2.2. The table contains the true value for each parameter, the
empirical mean of the estimates among the 1,000 simulations, the empirical MSE
of the estimates among 1,000 simulations, and the coverage probability of the 95%
confidence interval computed from the inverse of the information matrix and a normal
approximation, i.e. estimate ± 1.96 standard deviations. The true value of ∆ is
simply µ1 − µ0 = 0.2, and true values of ∆∗ and ∆∗∗ are the average over 1,000
simulations assuming all information is known for each subject. Since ∆, ∆∗, and ∆∗∗
are functions of parameters, the corresponding variance estimates of their estimates
are calculated with the delta method.
Based on Table 2.2, it can be seen that all parameter estimates are unbiased and
the coverage of the 95% confidence intervals are very close to 0.95. Table 2.3 sum-
marizes the finite sample properties of our methods with different rules for switching
treatment arms. The last six columns contain the empirical mean and MSE of each
parameter with switching rules that differ from the ones used with the results in
Table 2.2. Switching rule 2 (SR2) shows the performance when both of thresholds
for switching (exp(−0.7) = 0.50 for the treatment arm and exp(−1.0) = 0.37 for the
control arm) are greater than the true medians. Switching rule 3 (SR3) illustrates
the result when both of the switching thresholds (exp(−1.4) = 0.25 for the treatment
arm and exp(−1.7) = 0.18 for the control arm) are less than the true medians. In
switching rule 4 (SR4), threshold for the treatment arm (exp(−1.3) = 0.27) is less
than the true median (exp(−1.1) = 0.33) when the threshold for the control arm
(exp(−1.1) = 0.33) is greater than the true median (exp(−1.3) = 0.27). The results
presented in Table 2.3 demonstrate that estimation is relatively unaffected by the
actual switching rule that is used.
Since our methods are fully parametric, we also examine the performance of our
methods when some of the assumptions are violated. Table 2.4 summarizes simu-
lation results based upon data drawn from a log-Gamma distribution rather than a
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Table 2.2: Finite sample properties of estimating parameters based upon 1,000 sim-
ulations of a clinical trial with 200 patients in each arm. Patients are
allowed to switch at disease progression if their progression time is less
than exp(−1.1) = 0.33 (treatment arm) or exp(−1.3) = 0.27 (control
arm); MSE = mean squared error; CP = coverage probability for 95%
confidence interval.
True
Parameter Value Mean MSE CP
µ0 -1.30 -1.30 0.03 0.91
µ1 -1.10 -1.11 0.03 0.92
µ2 -1.20 -1.20 0.02 0.95
µ0E -0.50 -0.51 0.03 0.95
σ20 2.00 1.99 0.13 0.92
σ21 1.80 1.78 0.13 0.89
σ22 1.30 1.32 0.07 0.93
σ20E 2.00 2.00 0.21 0.92
σ21E 3.49 3.44 0.47 0.95
ρ1 0.58 0.57 0.05 0.89
ρ2 0.50 0.50 0.02 0.92
ρ3 0.10 0.11 0.03 0.93
p10 0.60 0.60 0.00 0.94
p11 0.50 0.50 0.00 0.95
∆ 0.20 0.20 0.02 0.96
∆∗ 0.69 0.68 0.11 0.95
∆∗∗ 0.19 0.18 0.02 0.95
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Table 2.3: Comparison of finite sample properties of estimating parameters based
upon 1,000 simulations of a clinical trial with 200 patients in each arm
for a variety of stopping rules. SR2 = Patients are allowed to switch at
disease progression if their progression time is less than exp(−0.7) = 0.50
(treatment arm) or exp(−1.0) = 0.37 (control arm); SR3 = Patients are
allowed to switch at disease progression if their progression time is less than
exp(−1.4) = 0.25 (treatment arm) or exp(−1.7) = 0.18 (control arm); SR4
= Patients are allowed to switch at disease progression if their progression
time is less than exp(−1.3) = 0.27 (treatment arm) or exp(−1.1) = 0.33
(control arm); MSE = mean squared error; CP = coverage probability for
95% confidence interval.
True SR2 SR3 SR4
Parameter Value Mean MSE Mean MSE Mean MSE
µ0 -1.30 -1.30 0.03 -1.30 0.02 -1.31 0.03
µ1 -1.10 -1.10 0.03 -1.11 0.03 -1.11 0.03
µ2 -1.20 -1.20 0.02 -1.20 0.02 -1.20 0.03
µ0E -0.50 -0.51 0.03 -0.51 0.03 -0.51 0.03
σ20 2.00 2.00 0.13 1.99 0.12 1.99 0.13
σ21 1.80 1.78 0.13 1.78 0.13 1.78 0.13
σ22 1.30 1.31 0.06 1.32 0.07 1.32 0.08
σ20E 2.00 1.99 0.21 2.00 0.21 1.99 0.21
σ21E 3.49 3.44 0.47 3.44 0.48 3.42 0.47
ρ1 0.58 0.57 0.04 0.57 0.05 0.57 0.05
ρ2 0.50 0.50 0.02 0.50 0.02 0.49 0.03
ρ3 0.10 0.11 0.02 0.11 0.03 0.11 0.03
p10 0.60 0.60 0.00 0.60 0.00 0.60 0.00
p11 0.50 0.50 0.00 0.50 0.00 0.50 0.00
∆ 0.20 0.20 0.02 0.20 0.02 0.20 0.02
∆∗ 0.69 0.68 0.11 0.68 0.12 0.68 0.12
∆∗∗ 0.19 0.19 0.02 0.18 0.02 0.18 0.02
23
lognormal distribution. The following approach is used to generate draws from a mul-
tivariate Gamma distribution. First, a vector of {Qi1, Qi2, Qi3, Qi4} is generated for
patient i from a mean-zero multivariate normal distribution that has variance matrix

1 ρ1 ρ2 ρ4
ρ1 1 ρ3 ρ5
ρ2 ρ3 1 ρ6
ρ4 ρ5 ρ6 1

(2.4)
Then Ti0 is calculated with {Ti0 = B(Φ(Qi1);κ1, θ1), where Φ(x) is the CDF of the
standard normal distribution and B(w;κ1, θ1) is the inverse CDF of a Gamma dis-
tribution with shape parameter κ1 and scale parameter θ1. κ1 and θ1 are chosen so
that logarithm of a variable with this Gamma distribution has a mean of µ0 and a
variance of σ20. Similarly, Ti1, Gi0, and TGi0 are calculated with B(Φ(Qi2);κ2, θ2),
B(Φ(Qi3);κ3, θ3), and B(Φ(Qi4);κ4, θ4). {κ2, θ2}, {κ3, θ3}, and {κ4, θ4} are chosen
based on the values of {µ1, σ21}, {µ2, σ22}, and {µ0E, σ20E} accordingly. Specifically,
in the 1,000 simulations summarized in Table 2.4, we have {κ1, θ1} = {0.88, 0.60},
{κ2, θ2} = {0.94, 0.66}, {κ3, θ3} = {1.18, 0.41}, and {κ4, θ4} = {0.88, 1.33}. We note
that although this approach does provide a vector of correlated Gamma random vari-
ables, the actual correlation matrix for the resulting vector is not exactly the same
as the matrix in (2.4).
It can be seen that although the parameter estimates are biased, the treatment
effects ∆, ∆∗ and ∆∗∗ estimates are close to their true values. Note that in practice,
the proposed parametric model can be easily extended to other distributions such
as Gamma if the observed distribution is not likely to be normal distributed. We
relegate comparing our methods to existing methods in the next section after we first
develop methods to reduce the inherent bias in the IPE algorithm of Branson and
Whitehead with multivariate normal data.
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Table 2.4: Comparison of finite sample properties of estimating parameters based
upon 1,000 simulations of a clinical trial with 200 patients in each arm
when distributions of event times are gamma rather than normal; Patients
are allowed to switch at disease progression if their progression time is
less than exp(−1.1) = 0.33 (treatment arm) or exp(−1.3) = 0.27 (control
arm); MSE = mean squared error; CP = coverage probability for 95%
confidence interval.
True
Parameter Value Mean MSE CP
µ0 -1.30 -1.14 0.04 0.81
µ1 -1.10 -0.92 0.05 0.81
µ2 -1.20 -1.22 0.02 0.95
µ0E -0.50 -0.53 0.03 0.98
σ20 2.00 2.40 0.43 0.77
σ21 1.80 2.37 0.63 0.71
σ22 1.30 1.55 0.25 0.87
σ20E 2.00 2.36 0.73 0.83
σ21E 3.49 4.03 1.55 0.86
ρ1 0.58 0.36 0.09 0.74
ρ2 0.50 0.65 0.04 0.51
ρ3 0.10 0.08 0.02 0.92
p10 0.60 0.62 0.00 0.91
p11 0.50 0.53 0.00 0.89
∆ 0.20 0.21 0.02 0.98
∆∗ 0.74 0.80 0.23 0.94
∆∗∗ 0.20 0.20 0.02 0.97
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2.5 Modifying IPE to Accomodate Multivariate Normality
In the IPE algorithm of Branson and Whitehead (2002), if a patient in the control
arm switches to the treatment arm when their disease progresses, their latent time
from randomization to death that would have been observed had the patient not
switched is calculated as Ti0 + exp(−ηˆ)Gi1. In this formulation, exp(η) is assumed to
be both (i) the ratio E(Gi1)/E(Gi0), and (ii) the treatment effect exp(∆
∗) defined in
Section 2.2. However, quantities (i) and (ii) are very different under the multivariate
normal model we have used to generate our data. Another reason for the difference
between (i) and (ii) is that the decision of whether a patient switches their treatment
arm depends on the disease progression time Ti0, so that even when quantities (i) and
(ii) are the same, the calculated latent time Ti0 + exp(−ηˆ)Gi1 is still biased.
Recall that we assume log(Ti0), log(Ti1), and log(Gi0) follow a multivariate normal
distribution defined in (2.1), with the distribution of log(Gi1) defined by log(Gi1) =
log(Gi0)+log(Ti1)−log(Ti0). A patient in the control arm will switch to the treatment
group after disease progression if their time to disease progression for this patient is
earlier than a certain value. This patient’s latent time to death (the one that would
have been observed in the absence of switching) would be Ti0 +Gi0, which based upon
the definition of treatment effect in the IPE algorithm should equal Ti0 +exp(−η)Gi1.
Now, conditional upon Ti0 = ti0, we have:
E(Ti0 +Gi0 | Ti0 = ti0) = E(Ti0 + exp(−η)Gi1 | Ti0 = ti0)
= E(Ti0 + [Gi1 ∗ E(Gi0)/E(Gi1)] | Ti0 = ti0)
so that
E(Gi0 | Ti0 = ti0)E(Gi1) = E(Gi1 | Ti0 = ti0)E(Gi0)
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resulting in the requirement that
E(Gi1 | Ti0 = ti0)
E(Gi0 | Ti0 = ti0)
E(Gi0)
E(Gi1)
= 1 (2.5)
Using earlier notation, we know
E(Gi1 | Ti0 = ti0)
E(Gi0 | Ti0 = ti0) =
exp(µ˜i3 + σ˜
2
3/2)
exp(µ˜i2 + σ˜22/2)
= exp([µ˜i3 − µ˜i2] + [σ˜23 − σ˜22]/2)
= exp{µ1 − log ti0 + ρ1σ1/σ0(log ti0 − µ0)
+σ21(1− ρ21)/2 + σ1σ2(ρ3 − ρ1ρ2)}
and
E(Gi0)
E(Gi1)
=
exp(µ2 + σ
2
2/2)
exp{µ1 + µ2 − µ0 + σ20/2 + σ21/2 + σ22/2− ρ1σ0σ1 − ρ2σ0σ2 + ρ3σ1σ2}
= exp{−µ1 + µ0 − σ20/2− σ21/2 + ρ1σ0σ1 + ρ2σ0σ2 − ρ3σ1σ2}
Thus, we can express the ratio in Equation (2.5) as
log
{
E(Gi1 | Ti0 = ti0)
E(Gi0 | Ti0 = ti0)
E(Gi0)
E(Gi1)
}
= (ρ1σ1/σ0 − 1)(log ti0 − µ0)− ρ21σ21/2
− σ20/2 + ρ1σ0σ1 + ρ2σ0σ2 − ρ1ρ2σ1σ2. (2.6)
In order to better examine the magnitude to which the equality in Equation (2.5)
is violated, we make two further assumptions to simplify Equation (2.6). The first
assumption is that variance of log(Gi0) = σ
2
2/2, is equal to variance of log(Gi1) =
σ20/2 + σ
2
1/2 + σ
2
2/2 − ρ1σ0σ1 − ρ2σ0σ2 + ρ3σ1σ2. Such an assumption is biologically
plausible and is often used by many models, such as the accelerated failure time
(AFT) model. Under this assumption, the logarithm of the ratio becomes (ρ1σ1/σ0−
1)(log ti0 − µ0) + (1− ρ21)σ21/2 + (ρ3 − ρ1ρ2)σ1σ2. Our second assumption is that Ti1
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and Gi0 are independent given Ti0 = ti0 so that we have ρ3 = ρ1ρ2, which further
simplifies Equation (2.6) to be (ρ1σ1/σ0−1)(log ti0−µ0)+(1−ρ21)σ21/2. As mentioned
in Section 2.2, it is reasonable to assume that ρ1σ1/σ0−1 is negative, so that Equation
(2.6) is strictly greater than zero when log ti0 < µ0. Therefore, the latent event time
will be biased for patients in the control arm who switch to the treatment arm after a
relatively early recurrence of disease. As a result, application of the IPE algorithm of
Branson and Whitehead (2002) leads to potentially biased treatment effect estimates.
To remedy this bias in the IPE algorithm, the latent event times for control arm
patients who switch to the treatment arm should not be computed as Ti0 +Gi1/∆
∗, in
which ∆∗ is constant for all values of Ti0, but should instead be Ti0 +Gi1/[∆∗τ(ti0)],
in which τ(ti0) = exp[(ρ1σ1/σ0 − 1)(log ti0 − µ0)] and varies by when a subject had
disease progression. Notice that τ(ti0) does not contain all quantities in Equation
(2.6), but only the parameters related to the mean change of log Ti0 after treatment
arm switching. The remaining parameters in Equation (2.6) may vary significantly
for different assumed distributions for Ti0, Ti1, Gi0, and Gi1; thus we ignore these
parameters in order to create an approach fairly robust to distributional assumptions.
Nonetheless, computation of τ(ti0) is less straightforward than computation of
∆∗. Thus, we make a further simplifying assumption that the variance of log(Ti0)
is equal to variance of log(Ti1), i.e. σ
2
1 = σ
2
0, so that computation of τ(ti0) only
requires estimates of µ0 and ρ1. Direct estimation of µ0 (denoted as µˆ0) is possible
because Ti0 is fully observed, but ρ1 cannot be directly estimated as it expresses the
within-patient association of Ti0 and Ti1, one of which will be latent for each patient.
Instead, one must assign a suitable value ρ∗1 to ρ1 and perform a sensitivity analysis
across a range of values for ρ1 regarding the overall performance of the IPE algorithm.
We define our approach of replacing ∆∗ with ∆∗τˆ(ti0) as IPE Adjustment 1, where
τˆ(ti0) = exp[(ρ
∗
1 − 1)(log ti0 − µˆ0)].
Because Gi1 and Gi0 are only observed after treatment switching, E(Gi1)/E(Gi0)
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cannot be correctly estimated from the data, making it impossible to confirm if
E(Gi1)/E(Gi0) is equal to ∆
∗, which is one of the assumptions of the IPE algo-
rithm. However, because both Ti1 and Ti0 are observed prior to treatment switch-
ing, we can estimate E(Ti1)/E(Ti0), which is similar to the inestimable quanti-
ty E(Gi1)/E(Gi0). If we take Equation (2.6) and substitute E(Gi1)/E(Gi0) with
E(Ti1)/E(Ti0) = exp{(µ0 + σ20/2)− (µ1 + σ21/2)}, we have
log
{
E(Gi1 | Ti0 = ti0)
E(Gi0 | Ti0 = ti0)
E(Ti0)
E(Ti1)
}
= (ρ1σ1/σ0 − 1)(log ti0 − µ0)
− ρ21σ21/2 + σ20/2 + (ρ3 − ρ1ρ2)σ1σ2. (2.7)
The minor difference between Equations (2.6) and (2.7) is explained by variance
parameters that were omitted in IPE Adjustment 1. Thus, we can take IPE Ad-
justment 1, ∆∗τˆ(ti0), and replace ∆∗ with E(Ti1)/E(Ti0), giving us IPE Adjustment
2, [Ê(Ti1)/Ê(Ti0)]τˆ(ti0), which attempts to limit dependence on the unverifiable as-
sumption that ∆∗ = E(Gi1)/E(Gi0). Note that because ∆∗ is no longer used in the
estimating procedure, iteration is avoided in IPE Adjustment 2.
Now that we have developed methods for reducing the bias of the IPE algorithm,
we present simulation results in Table 2.5 that compare the performance of our pro-
posed methods with other existing methods for estimation of ∆∗. The intent-to-treat
and per-protocol analyses used an AFT model assuming a log-normal distribution,
as did the standard IPE, and IPE with Adjustments 1 and 2. Data were simulated
similar to the procedure described in Section 2.4, except that no censoring was in-
corporated into the data. The true treatment effect is ∆∗ = 0.71 and 1,000 data sets
were simulated. The effects of Adjustments 1 and 2 to the IPE algorithm were ex-
amined using three different values of ρ∗1 = {0.2, 0.5, 1.0}. Table 2.5 displays the bias
and MSE across the 1,000 simulations. We acknowledge that most of the competing
methods are semiparametric or nonparametric, and thus our proposed method has
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the smallest MSE. Therefore another comparison is illustrated under the last column
labeled as MSE*. If we suppose that the unobserved Gi0 for control arm patients
who switch and the unobserved Gi1 for treatment arm patients who switch can actu-
ally be observed, then we consider the ratio of the sample means of overall survival
time between the two arms as a gold standard nonparametric estimate of ∆∗ and we
call this the “true treatment effect” for each simulation. For each method, MSE* is
defined to be the averaged squared difference between the estimate from the method
and the “true treatment effect” and provides a measure of how well a method can
recover the information lost due to switching treatment arms.
With regard to bias, we see in Table 2.5 that our proposed method is unbiased
and the IPE algorithm has the least bias among all other methods examined. The
intent-to-treat analysis underestimates the treatment effect as expected, and down-
ward bias also exists for the per-protocol methods. Exclusion of patients who switch
treatment leads to bias because exclusion is a function of when subjects experience
disease progression, and treating treatment switching as a censoring event also creates
bias because the censoring is informative. The bias occurring in a Cox proportional
hazards model with treatment arm as a time-varying covariate occurs because the as-
sumption of proportional hazards (PH) is violated. This last approach has the largest
bias because the PH assumption holds for the entire sample of data, while the bias
of the other approaches only related to assumption made about patients who switch
treatment arms.
The bias of the treatment effect estimate from the IPE algorithm using Adjustment
1 is small and appears to be insensitive to the value of ρ∗1; note that when ρ
∗
1 = 1,
τˆ(ti0) is actually one, and using IPE with Adjustment 1 is equivalent to the original
IPE algorithm. The bias of the treatment effect estimate for the IPE algorithm with
Adjustment 2 appears to be more sensitive to the value of ρ∗1 which indications of
non-negligible bias with values of ρ∗1 > 0.50. Although bias of Adjustment 2 is slightly
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Table 2.5: Finite sample properties of different methods for estimating a known treat-
ment effect of ∆∗ = 0.71. There were 200 patients in each arm and 1,000
simulations were conducted. Proposed: parametric MLE assuming mul-
tivariate normality; ITT: Intent-to-treat analysis; PPES: per-protocol ex-
cluding data from those who switch treatment arms; PPCS: per-protocol
treating disease progression as a censoring event for future death; CoxTV:
Cox proportional hazards model with treatment arm as a time-varying
covariate; IPE: iterative parameter estimation algorithm by Branson and
Whitehead (2002); A1 and A2: Adjustment methods 1 and 2 for IPE as
described in Section 2.5; MSE: mean-squared error; MSE*: MSE with
recovery of latent event times.
Assumed
Method Value for ρ∗1 Bias MSE MSE*
Proposed · 0.00 0.05 0.064
ITT · -0.12 0.12 0.011
PPES · -0.05 0.12 0.003
PPCS · -0.04 0.12 0.003
CoxTV · -0.25 0.12 0.104
IPE · 0.01 0.14 0.005
IPE A1 0.2 0.02 0.13 0.003
0.5 0.02 0.13 0.003
1.0 0.01 0.14 0.005
IPE A2 0.2 -0.03 0.11 0.001
0.5 -0.04 0.11 0.001
1.0 -0.08 0.11 0.005
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larger than bias of Adjustment 1, we should point out that it is because there is a
small difference between the value of 0.71 for ∆∗ calculated from the true parameters
and the average of the “true treatment effect” over the 1,000 simulation, which is
0.68. If the latter value had been assumed to be the true value of ∆∗, the bias of
Adjustment 2 is much less.
We acknowledge that our method has the lowest MSE among the methods because
the data are simulated from our assumed model. However, the corresponding MSE*
for our method is the second largest among all approaches because of the parametric
estimation relative to the other semi- and non-parametric methods. Although the
true value of ρ1 in our simulation is 0.58, we observe that the MSE and MSE* for the
IPE algorithm with Adjustment 2 are very small when ρ∗1 is 0.2 or 0.5, demonstrating
that much of the lost information can be recovered by the IPE algorithm when using
Adjustment 2 even if the specified ρ∗1 is less than ρ1. Generally, we suggest that
Adjustment 2 with ρ∗1 between 0.0 and 0.5 should be used in practice because: (i) ρ1
is unlikely to be very large in realistic settings, and (ii) the recommended value for
ρ∗1 should be less than that for ρ1 if DT i is not equal to but positively correlated with
DGi.
We chose to simulate data without censoring because White (2006) pointed out
that the recensoring approach proposed by Branson and Whitehead (2002) for the
IPE algorithm was potentially biased and White (2006) provided a corrected version
of recensoring to use with the IPE algorithm. Unfortunately, this modified recen-
soring approach cannot be applied to our approach because the censoring times are
not observed for uncensored patients. A potential approach to recensoring for our
approach is still under investigation.
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2.6 Discussion
Our work has shown that when treatment arm switching depends on the observed
progression time of patients, the IPE adjustment of Branson and Whitehead (2002)
may be biased. This is because the causal effect can be altered after treatment
switching selection. For the same reason, if treatment switching depends on some-
thing that is not measured in the data set (for example, an investigator’s judgment
and/or prognosis), unverifiable assumptions are required to identify the effect of these
unmeasured factors. In this chapter, we propose a robust approach to address the
issue when treatment switching depends on the observed progression time, and we
assume independence between treatment switching and the future event time given
observed progression time. This assumption, although weaker than the assumption-
s required by IPE, is still questionable in practice, so it is highly recommended to
collect more variables associated with both treatment switching and the future event
time to weaken the unverified assumption.
Our assumption that DT i ≡ DGi ≡ DTGi may appear strong but is intuitive. It
provides an idea to understand the association between the causal effect of treatment
with survival both before progression and after progression and leads to our proposed
adjustments for treatment arm switching. The assumption can be relaxed by assum-
ing DGi is positively correlated with DT i instead of equal to DT i. Note that although
the correlation between DGi and DT i (denoted as ρTG) may be unidentifiable, the ro-
bust approaches proposed in Section 2.5 with ρ1 replaced by ρ1ρTG could be applied,
although a sensitivity analysis for the assumed value of ρ1ρTG would still be required.
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CHAPTER III
Missing Not at Random Models for Masked
Clinical Trials with Dropouts
3.1 Introduction
Randomized controlled trials (RCTs) are the gold standard for assessing the effec-
tiveness of health interventions. However, missing data are common in many experi-
mental studies and undermine the benefits of randomization. Although missing data
can be reduced by preventive measures in the design and conduct of clinical trials
(Little et al., 2012), some missing values are often unavoidable.
Simple methods such as complete case analysis and last observation carried for-
ward imputation can yield severe bias or loss of efficiency (National Research Council,
2010). Alternative missing data adjustment methods often assume that the missing
data are missing at random (MAR), in the sense that missingness does not depend on
the missing values after conditioning on the observed data (Rubin, 1976). Approaches
based on MAR include ignorable likelihood-based methods such as parametric multi-
ple imputation (Rubin, 1987) and maximum likelihood (ML) estimation, and inverse
probability-weighted methods (Robins et al., 1995). However, in many settings, such
as when data on outcomes are missing because of adverse events or lack of treatment
efficacy, missingness depends on the missing values, in which case the MAR assump-
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tion is violated. Such mechanisms are called missing not at random (MNAR), or
non-ignorable (Little and Rubin, 2002).
Joint models for the outcomes and missing indicators are usually required for
non-ignorable missing data mechanisms. Little (1993) considered two classes of joint
models: selection models and pattern-mixture models. Selection models factorize the
joint model of outcomes and missing indicators into a model for the marginal out-
comes and another model of missing indicators conditional on the possibly unobserved
outcomes. Pattern-mixture models factorize the joint model into a model of missing
data patterns and another model for outcomes given missing data patterns. In either
approach, unverifiable restrictions or assumptions are required to identify the param-
eters (Fitzmaurice et al., 2005). Researchers have proposed sensitivity analyses to
address this issue (Little and Rubin, 2002; Scharfstein et al., 1999; National Research
Council, 2010), but in practice only a limited set of MNAR models can be assessed.
Masked (or blinded) experiments conceal the treatment assignment from the sub-
ject (and perhaps also from the clinician) to prevent the potential bias caused by
knowing this information. We suggest that, since the specific treatment received
is unknown, masking justifies the assumption that missingness does not depend on
treatment assignment after conditioning on outcomes and side effects. That is, any
treatment effect on missingness is fully mediated through outcome and side effect-
s. Since missingness of outcomes is allowed to depend on the outcomes values, this
assumption is MNAR – we call the assumption masked missing not at random (MM-
NAR). Even if some participants guess the treatment group to which they are as-
signed, their judgement on whether to stay in the study still depends primarily on
outcomes and side effects, so our proposed assumption may be more plausible than
MAR. Unlike MAR, MMNAR is not always sufficient to identify the parameters, as
discussed for categorical and continuous data models in Section 3.2.
Our motivating example is the TRial Of Preventing HYpertension (TROPHY)
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study (Julius et al., 2006), a randomized, double-blind clinical trial that examined
whether early treatment of prehypertensive patients might prevent or delay the de-
velopment of hypertension. After the entry criteria were met, the participants were
randomized to treatment or placebo. In the first 2-year phase, subjects in the treat-
ment group received candesartan at a dose level of 16mg daily. This was followed by
the second 2-year phase, in which all study patients received placebo. For subjects in
both groups, return visits were scheduled every 3 months, with two additional visits
at month 1 and month 25. At each clinic visit, sitting and resting blood pressures
were recorded along with adverse effects. Throughout the 4-year period, subjects and
study investigators remained masked to the original treatment assignment. Our anal-
ysis was to determine whether for patients with prehypertension, 2 years of treatment
(candesartan) would reduce the incidence of hypertension for up to 2 years after active
treatment was discontinued. Among 772 randomized patients, 109 of them discon-
tinued participation before reaching the trial end point. This missing data problem
was originally addressed with the last observation carried forward (LOCF) method,
in which the blood pressure recorded at the last clinic visit was carried forward. We
apply our proposed MMNAR model to this study.
The remainder of the chapter is organized as follows. In Section 3.2, we formalize
our assumption about the missing data mechanism and incorporate it in two models
for categorical and continuous outcomes, along with associated estimation procedures.
Section 3.2.4 describes simulation studies that compare our methods with alternatives.
In Section 3.3, we analyze the TROPHY data. We conclude with a discussion in
Section 3.4.
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3.2 Masked Missing Not at Random (MMNAR) Models
3.2.1 The MMNAR Assumption
We consider a randomized clinical trial with two or more arms and n subjects.
The full data for ith individual are given by Xi, Zi, Si, Yi, where (a) Xi denotes the
assigned treatment arm, (b) Zi denotes a set of baseline covariates, (c) Si denotes
side effects recorded in the course of the study, and (d) Yi denotes an outcome of
interest at the end of the study. The variables Xi, Zi, and Si are assumed to be fully
recorded, but some values of the outcome Yi are missing. We define a missing data
indicator Mi, which equals 1 if Yi is missing and 0 if Yi is observed. The data for
ith individual are modeled by the joint distribution of the outcome, side effects and
missing data indicator given the covariates and treatment indicators, with density
f(Yi, Si,Mi|Zi, Xi, θ), where θ is the set of model parameters.
We assume observations are independent. Then the missing data mechanism is
missing at random (MAR, (Rubin, 1976)) if
Pr(Mi = 1|Yi, Si, Zi, Xi, θ) = Pr(Mi = 1|Si, Zi, Xi, θ), (3.1)
that is, probability of being missing can depend on observed side effects, covariates,
and treatment indicators, but does not depend on the outcomes Yi after conditioning
on these variables. An equivalent assumption is
f(Yi|Si, Zi, Xi,Mi = 1, θ) = f(Yi|Si, Zi, Xi,Mi = 0, θ), (3.2)
that is, the distribution of Yi given Si, Zi, Xi is the same for cases with Y missing as
for cases with Y observed. Under the MAR assumption of Eqs. (3.1) or (3.2), infer-
ence for the parameters θ does not require a model for the missing data mechanism
(National Research Council, 2010).
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Most standard models for analyzing the data make the MAR assumption, but
in practice, there are often situations where missingness is likely to depend on the
outcome Y , so MAR is not valid. In masked trials, it seems plausible that after
conditioning on relevant observed information, namely side effects and outcomes,
missingness does not depend on the treatment assigned. This motivates the following
alternative to MAR:
Pr(Mi = 1|Xi, Yi, Si, Zi, θ) = Pr(Mi = 1|Yi, Si, Zi, θ), (3.3)
that is, the probability that Y is missing is allowed to depend on the side effects,
covariates and outcome, but does not depend on the assigned treatment. We call
this the masked MNAR (MMNAR) assumption. Like MAR, Eq. (3.3) cannot be
verified from the observed data, but we suggest that it can be justified by the nature
of masked experiments. It is easy to show (see Appendix 3.5.1 for details) that Eq.
(3.3) is equivalent to
f(Xi|Yi, Si, Zi,Mi = 1) = f(Xi|Yi, Si, Zi,Mi = 0) (3.4)
so the MMNAR assumption implies that the conditional probability of being in a
treatment group given outcomes, side effects, and covariates, is the same for individ-
uals with Yi observed and individuals with Yi missing.
3.2.2 Some MMNAR models
We describe some MMNAR models that assume Xi and Mi are categorical vari-
ables, but consider various models for the distribution of Si and Yi.
Example 1. A categorical MMNAR model. Suppose there are no covariates
Zi, and Xi, Yi, Si, and Mi are all categorical; Xi has J categories, corresponding
to J treatment arms, Yi has K categories corresponding to K possible outcomes,
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and Si has L categories, corresponding to no side effect or L − 1 different types of
side effects. These, together with the binary missing data indicator Mi, form a 4-
way J × K × L × 2 contingency table, which is incompletely observed since Yi is
missing for cases with Mi = 1. We assume that conditional on the sample size n
the cell counts follow a multinomial distribution with parameters γ = {γjklm) where
γjklm = Pr{Xi = j, Yi = k, Si = l,Mi = m}. We can express the cell probabilities
{γjklm} as a saturated loglinear model
log γjklm = α
(0) + α
(1)
j + α
(2)
k + α
(3)
l + α
(4)
m + α
(12)
jk + α
(13)
jl + α
(14)
jm + α
(23)
kl
+α
(24)
km + α
(34)
lm + α
(123)
jkl + α
(124)
jkm + α
(134)
jlm + α
(234)
klm + α
(1234)
jklm , (3.5)
where the α terms are constrained to sum to zero over any of their subscripts. This
model has 2JKL − 1 parameters. It is not identified without restrictions, because
the observed data only provides estimates for JKL+ JL− 1 parameters – there are
JKL cell counts for cases with Y observed, JL cell counts for cases with Y missing,
less one for the contraint that the probabilities sum to one. However, under the
MMNAR assumption, there are no associations between Xi and Mi given Yi and Si, so
α
(14)
jm = α
(124)
jkm = α
(134)
jlm = α
(1234)
jklm = 0. In total, (J−1)KL parameters are set to zero, so
this MMNAR model has 2JKL−1−(J−1)KL = JKL+KL−1 unknown parameters.
This model is identified if and only if JKL+KL− 1 ≤ JKL+ JL− 1⇐⇒ K ≤ J ,
that is, the number of treatment groups is greater than or equal to the number of
categories of outcomes (See Appendix 3.5.2 for more details). ML estimates can be
readily computed using an EM algorithm.
This saturated categorical MMNAR model can be written as (XY S, Y SM), using
the notation in Agresti (2002) which lists the highest-order associations for each
variable. It may require a large sample size to yield estimates with sufficient precision,
so unsaturated models that further constrain the parameters are also of interest. Table
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3.1 lists all hierarchical log-linear models that (a) include the YM association (not
MAR models), and (b) include at least one of the XS and XY associations (the
treatment assignment is associated with either side effects or outcomes). The table
summarizes the degrees of freedom for these models and the conditions required for
them to be identified. For example, if we assume there is no three-way association
Y SM , as in model 5 in Table 3.1, there are (K − 1)(L − 1) less parameters in the
model. This model is identified if K ≤ JL−L+1, a much less stringent condition than
K ≤ J . These models can be further extended by including categorical covariates Z.
Table 3.1: All categorical models assuming MMNAR that include YM and at least
one of XS and XY .
Model Symbol Model DF Identified if
1 XY S, Y SM (J + 1)KL− 1 K ≤ J
2 XY,XS, Y SM 2KL+ JL+ JK − J − L−K K ≤ J
3 XY, Y SM 2KL+ (J − 1)K − 1 K ≤ J
4 XS, Y SM 2KL+ (J − 1)L− 1 Never
5 XY S, SM, YM JKL+K + L− 2 K ≤ JL− L+ 1
6 XY,XS, Y S, SM, YM KL+ JL+ JK − J − 1 K ≤ JL− L+ 1
7 XY, Y S, SM, YM KL+ JK + L− 2 K ≤ JL− L+ 1
8 XS, Y S, SM, YM KL+ JL+K − 2 Never
9 XY,XS, SM, YM JL+ JK − J +K + L− 2 K ≤ J
10 XY, SM, YM JK +K + 2L− 3 K ≤ J
11 XS, SM, YM JL+ 2K + L− 3 Never
12 XY S, YM JKL+K − 1 K ≤ JL
13 XY,XS, Y S, Y M KL+ JL+ JK − J − L K ≤ JL
14 XY, Y S, Y M KL+ JK − 1 K ≤ JL
15 XS, Y S, Y M KL+ JL+K − L− 1 K ≤ L
16 XY,XS, YM JL+ JK − J +K − 1 K ≤ J
17 XY, S, Y M JK +K + L− 2 K ≤ J
18 XY, YM JK +K + L− 3 K ≤ J
19 XS, YM JL+ 2K − 2 Never
Example 2. A normal MMNAR model. We now suppose Xi remains
categorical, with two treatment arms, a control arm (Xi = 0) and an experimental
arm (Xi = 1), but Yi is a continuous variable that (possibly after transformation) can
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be modeled as normal. No distributional assumption is made for Si and Zi.
Specifically, we assume the model of Mi given Xi, Si, and Zi is logit(Pr(Mi =
1|Xi = xi, Si = si, Zi = zi))=βM0 + βMXxi + βMSsi + βMZzi. The conditional distri-
bution of Yi given Xi, Mi, Si, and Zi is assumed to be
[Yi|Xi = xi,Mi = mi, Si = si, Zi = zi] ∼ N(βY 0 +βY Xxi+βYMmi+βY Ssi+βY Zzi, σ2)
whereN(µ, σ2) denotes the normal distribution with mean µ and variance σ2, assumed
to be the same for different xi, mi, si, and zi. Interactions are not included for
simplicity, but other more complex models can be considered and a table similar to
Table 3.1 can be generated. The set of parameters β is
{βM0, βMX , βMS, βMZ , βY 0, βY X , βYM , βY S, βY Z , σ2}
This model can be shown with some algebra to imply that logit(Pr(Mi = 1|Yi =
yi, Xi = xi, Si = si, Zi = zi, β))= αM0 + αMY yi + αMXxi + αMSsi + αMZzi, where
αM0, αMY , αMX , αMS, and αMZ are known functions of β. The MMNAR assumption
implies one restriction αMX = βMX − βYMβY X/σ2 = 0. Since there is only one
inestimable parameter βYM (which is caused by missingness of Yi when Mi = 1) in
the unconstrained model, the constrained model is just identified. The loglikelihood
is maximized by (a) calculating the ML estimates of βM0, βMX , βMS, βMZ with
all observations; (b) calculating the ML estimates of βY 0, βY X , βY S, βY Z with all
observations with observed Yi; and (c) calculating the estimated value of βYM =
βMXσ
2/βY X . Once the ML estimates are obtained, an multiple imputation procedure
(details in Appendix 3.5.3) (Rubin, 1987) can be used to draw inference. We label
this model the normal MMNAR model.
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3.2.3 Efficiency of MMNAR model estimates
The intersection of the MAR and MMNAR model (when both MAR and MMNAR
are true) is a restricted MAR model where missingness can depend on the side effects
and the covariates, but does not depend on the outcome or the treatment. That is:
Pr(Mi = 1|Xi, Yi, Si, Zi, θ) = Pr(Mi = 1|Si, Zi, θ),
We label this the MARSZ model. If MARSZ is the correct model, ML assuming
MAR is prefered to ML assuming MMNAR, since estimates of treatment effects (say
θ1) under MAR are more or equally efficient – a sketch of the proof is given in the
Appendix . Some simulation comparisons of the efficiency of these methods when
MARSZ is true are given in Section 3.2.4. The MMNAR model might be fitted as
a form of sensitivity analysis for deviations from MAR. If the estimates based on
the MMNAR model are similar to those based on MAR, the MAR analysis might
be favored on grounds of efficiency. But if the estimates are substantially different,
the MMNAR estimates might be preferred because the mechanism is more plausible.
More formally, a likelihood ratio test could be performed to check if the data are
consistent with MARSZ given MMNAR, but the power of this test may be limited.
3.2.4 Simulation Studies
Scenario 1&2. The categorical MMNAR model. Finite sample properties
of the categorical MMNAR model in Section 3.2.2 are explored via simulation. We
assume two treatment arms (J = 2), a binary outcome (K = 2), and two categories
of side effects (L = 2). Xi, Yi,Mi, Si for 400 subjects are drawn based on factorization
γjklm = γ(j)kl+γ+kl(m)γ+kl+. The specific parameter settings are shown in Table 3.2,
Scenario 1, and they imply that Pr(Xi = 1) = 0.5. After Xi, Yi,Mi, and Si are
generated, values of Yi for cases with Mi = 1 are deleted to make 40% of outcome
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values missing.
Table 3.2: Parameters used to generate categorical and normal models
Scenario 1: the categorical model when MMNAR is true.
{Yi, Si} {1, 1} {1, 2} {2, 1} {2, 2}
Pr(Yi, Si) 0.17 0.20 0.40 0.23
Pr(Xi = 1|Yi, Si) 0.94 0.24 0.57 0.28
Pr(Mi = 1|Yi, Si) 0.30 0.31 0.54 0.33
Scenario 2: the categorical model when both MMNAR and MAR are true.
{Si,Mi} {1, 0} {1, 1} {2, 0} {2, 1}
Pr(Si,Mi) 0.02 0.09 0.71 0.18
Pr(Xi, Yi|Si = 1) 0.08 0.26 0.52 0.14
Pr(Xi, Yi|Si = 2) 0.45 0.07 0.08 0.40
Scenario 3: the normal model when MMNAR is true.
Z1i Pr(Z1i = 1) = 0.4
Z2i|Z1i [Z2i|Z1i] ∼ N(1 + 0.2Z1i, 1)
Si|Xi, Z1i, Z2i logit(Si = 1|Xi, Z1i, Z2i) = 1− 2Xi + Z1i − 0.5Z2i
Mi|Si, Xi, Z1i, Z2i {βM0, βMX , βMZ1, βMZ2, βMS}={−0.5,−1, 2,−0.5, 1}
Yi|Mi, Si, Xi, Z1i, Z2i {βY 0, βY X , βY Z1, βY Z2, βY S, βYM , σ2}={−1, 1, 2, 0.5,−1,−1, 1}
Scenario 4: the normal model when both MMNAR and MAR are true.
Z1i Pr(Z1i = 1) = 0.4
Z2i|Z1i [Z2i|Z1i] ∼ N(1 + 0.2Z1i, 1)
Si|Xi, Z1i, Z2i logit(Si = 1|Xi, Z1i, Z2i) = 1− 2Xi + Z1i − 0.5Z2i
Mi|Si, Xi, Z1i, Z2i {βM0, βMX , βMZ1, βMZ2, βMS}={−0.5, 0, 2,−0.5, 1}
Yi|Mi, Si, Xi, Z1i, Z2i {βY 0, βY X , βY Z1, βY Z2, βY S, βYM , σ2}={−1, 1, 2, 0.5,−1, 0, 1}
Two other methods, complete case analysis and ML assuming MAR, are also
applied to the generated samples for comparison purposes. The ”before deletion”
data analysis, which assumes that we have access to all Yi, is also included as a
benchmark for comparison. Differences of Yi between groups ofXi, Pr(Yi = 1|Xi = 2)-
Pr(Yi = 1|Xi = 1), along with Pr(Yi = 1|Xi = 1) are of interest. We compare
estimates for each method and their estimated variances. Variance estimates for the
ML methods are computed from the inverse of the information matrix by the delta
method.
Table 3.3 presents the true parameter values, and for each method the empirical
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mean and empirical MSE of the estimates, and the coverage proportion (CP) of
the 95% confidence interval (CI), based on 1,000 simulated data sets. The 95%
confidence interval is calculated with a normal approximation, i.e. point estimate ±
1.96 standard deviations.
Table 3.3: Finite sample properties of four methods based upon 1,000 simulations of
a clinical trial with 400 patients. All of Xi, Yi, and Si are categorical.
In Scenario 1, MMNAR is true (Mi and Xi are independent given Yi and
Si). In Scenario 2, both MMNAR and MAR are true (Mi are independent
with Xi and Yi given Si). MSE = 10
4 × mean squared error. CP = 102 ×
coverage proportion for 95% confidence interval.
Method Parameter True Mean MSE CP
Scenario 1: the categorical model when MMNAR is true.
Before deletion Pr(Yi = 1|Xi = 1) 0.42 0.42 12 95.3
data analysis Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.09 -0.09 23 95.0
Complete case Pr(Yi = 1|Xi = 1) 0.42 0.49 83 60.0
analysis Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.09 -0.12 49 92.4
ML assuming Pr(Yi = 1|Xi = 1) 0.42 0.50 88 57.8
MAR Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.09 -0.16 80 82.0
ML assuming Pr(Yi = 1|Xi = 1) 0.42 0.42 72 98.0
MMNAR Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.09 -0.09 101 97.6
Scenario 2: the categorical model when both MMNAR and MAR are true.
Before deletion Pr(Yi = 1|Xi = 1) 0.82 0.82 7 96.1
data analysis Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.56 -0.56 17 93.9
Complete case Pr(Yi = 1|Xi = 1) 0.82 0.85 20 74.1
analysis Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.56 -0.66 118 37.8
ML assuming Pr(Yi = 1|Xi = 1) 0.82 0.82 12 97.9
MAR Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.56 -0.56 29 98.5
ML assuming Pr(Yi = 1|Xi = 1) 0.82 0.82 14 96.1
MMNAR Pr(Yi = 1|Xi = 2)-Pr(Yi = 1|Xi = 1) -0.56 -0.57 33 96.4
In Table 3.3, treatment effects from both complete case analysis and ML assuming
MAR are biased, showing the potential for bias when the missing data mechanism
is MNAR. Our proposed method is essentially unbiased with small MSE and cover-
age proportion very close to 95%, confirming as expected that our proposed model
outperforms the MAR model when MMNAR is true.
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It is of interest to compare ML under MMNAR and ML under MAR when Mi
does not depend on Xi or Yi given Si, so both methods are valid. Xi, Yi,Mi, Si
are drawn based on factorization Pr(Xi, Yi, Si,Mi) = Pr(Si,Mi)Pr(Xi, Yi|Si). More
specifical parameter setting can be found in Table 3.2, Scenario 2, which leads to
Pr(Xi = 1) = 0.5. After all Xi, Yi,Mi, and Si are generated, values of Yi for cases
with Mi = 1 are deleted to make 27% of outcome values missing. Results for 1,000
data sets simulated in this way are shown in Table 3.3.
The estimates from complete case analysis are biased. Both ML under MMNAR
and ML assuming MAR have small empirical bias, and confidence intervals close to
nominal 95% coverage. This is expected since model assumptions in both models
are satisfied. We noted above that ML assuming MAR is at least as efficient as ML
assuming MMNAR. In this simulation, ML under MMNAR is very close to ML under
MAR in terms of efficiency.
Scenario 3&4. The normal MMNAR model. Simulation studies are also
conducted to examine the performance of the normal MMNAR model. We consider
a design with an experimental group and a control group with 200 patients in each
group. We generate one binary covariate Z1i, one normal covariate Z2i, one binary
side effect Si, the missing indicator Mi, and the normal outcome Yi successively with
the parameters specified in Table 3.2, Scenario 3. The rate of missing data for this
scenario is 45%.
Before deletion data analysis, complete case analysis and the model assuming
MAR are compared with our proposed model in estimating E(Yi|Xi = 0) and E(Yi|Xi =
1)−E(Yi|Xi = 0). In complete case analysis, a general linear regression of Yi on Xi is
fitted for the subsample with Mi = 0. In ML estimates assuming MAR and MMNAR,
the multiple imputation described in Section 3.2.2 is used to estimate E(Yi|Xi = 0)
and E(Yi|Xi = 1) − E(Yi|Xi = 0). Table 3.4 presents the true value, the empir-
ical mean of the estimates, the empirical MSE of the estimates, and the coverage
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proportion of the 95% confidence intervals (CI) based on 1,000 simulations.
Table 3.4: Finite sample properties of four methods based upon 1,000 simulations of
a clinical trial with 400 patients. Xi, Z1i, Mi and Si are categorical. Yi,
and Z2i are continuous. In Scenario 3, MMNAR is true (Mi and Xi are
independent given Yi, Z1i, Z2i, and Si). In Scenario 4, both MMNAR and
MAR are true (Mi are independent with Xi and Yi given Z1i, Z2i, and Si).
MSE = 103 × mean squared error. CP = 102 × coverage proportion for
95% confidence interval.
Method Parameter True Mean MSE CP
Scenario 3: the normal model when MMNAR is true.
Before deletion E(Yi|Xi = 0) -0.93 -0.92 13 95.1
data analysis E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.69 1.67 24 95.4
Complete case E(Yi|Xi = 0) -0.93 -0.53 183 32.8
analysis E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.69 1.47 91 80.1
ML assuming E(Yi|Xi = 0) -0.93 -0.34 361 2.2
MAR E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.69 1.42 107 68.2
ML assuming E(Yi|Xi = 0) -0.93 -0.93 56 93.5
MMNAR E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.69 1.69 38 95.3
Scenario 4: the normal model when both MMNAR and MAR are true.
Before deletion E(Yi|Xi = 0) -0.35 -0.34 13 94.0
data analysis E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.43 1.43 26 93.9
Complete case E(Yi|Xi = 0) -0.35 -0.53 61 77.4
analysis E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.43 1.41 48 94.7
ML assuming E(Yi|Xi = 0) -0.35 -0.34 24 94.0
MAR E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.43 1.43 37 95.0
ML assuming E(Yi|Xi = 0) -0.35 -0.35 48 94.9
MMNAR E(Yi|Xi = 1)− E(Yi|Xi = 0) 1.43 1.44 37 95.3
Both complete case analysis and ML assuming MAR are biased, as expected.
Our proposed method has small empirical bias with variance estimates that yield
confidence intervals with close to nominal coverage. The comparisons between ML
assuming MAR and the proposed method, when both assumptions are satisfied, are
also presented in Table 3.4.
In this setting, Mi are independent with Xi and Yi given Z1i, Z2i, and Si. The
parameters for generating the samples are specified in Table 3.2, Scenario 4. The rate
of missing data for this scenario is 45%.
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As seen in Table 3.4, complete case analysis is biased, while the other two methods
have small empirical bias and have confidence intervals close to nominal 95% coverage.
As for the categorical MMNAR model simulation, the MSE of the treatment effect
estimates from the two methods are very similar. Here the loss of efficiency from the
MMNAR model is very small, but further investigation is needed to establish this
finding more generally.
3.3 Application
We illustrate the categorical MMNAR model described in Section 3.2.2 with the
TROPHY study (Julius et al., 2006). The population consisted of 772 patients en-
rolled at 71 centers, randomly assigned to one of the two groups: placebo (381) and
candesartan (391). Let xi be the binary treatment indicator with xi = 0 denoting
the placebo arm and xi = 1 denoting the candesartan arm. Let yi be the indicator
of hypertension being observed in the 4-year period for ith subject. Development of
hypertension was defined as the first appearance of one of the following outcomes:
systolic pressure of 140 mm Hg or higher or diastolic pressure of 90 mm Hg or higher,
for any three visits; systolic pressure of 160 mm Hg or higher or diastolic pressure of
100 mm Hg or higher for any visit; initiation of pharmacologic treatment; or systolic
pressure of 140 mm Hg or higher or diastolic pressure of 90 mm Hg or higher at the
visit at month 48. Among those 772 patients, 109 (55 in candesartan group) dropped
out before development of hypertension. Let mi be the missing data indicator for
yi with mi = 1 denoting subject i dropping out before yi was observed. If patien-
t i dropped out after development of hypertension, the value of mi was 0 because
yi = 1 was already observed. Therefore mi was likely to be related to yi and the
independence between yi and mi given other variables was questionable.
Two types of adverse effects were recorded. The first type contained severe adverse
effects (SAE), such as hospitalization, disability/incapacity, and some others. 88 out
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of the 772 subjects had at least one of SAE. The second type included other adverse
effects (OAE), such as exacerbation of back pain and sinusitis. For each subject,
OAE were recorded for most visits along with their severity (mild, moderate, or
severe) and whether OAE were related to treatment (probably, possible, or unlikely).
We summarize the adverse effects into two main categories, creating a binary adverse
effect variable Si for subject i. If subject i did not have SAE, and the recorded OAE
were unlikely to be related to treatment and were also not severe, si is defined to be
0 (506 subjects), otherwise si is 1 (266 subjects).
As discussed in Section 3.2.2, other covariates related to outcomes or missing
indicators could be included in the model to make the proposed assumption more
plausible. There were many baseline covariates recorded in this study, so some di-
mension reduction is needed. We perform two logistic regressions of mi and observed
yi on those baseline covariates for the control group patients and determine the asso-
ciations based on Nagelkerke’s pseudo R2. The baseline covariates are more strongly
associated with yi (Nagelkerke’s pseudo R
2 = 0.343) than with mi (Nagelkerke’s pseu-
do R2 = 0.135). Therefore we select the variables significantly related to yi (sex, race,
weight, BMI, and the baseline blood pressures measured at home), perform a logistic
regression of yi on them for the control group, and calculate the predicted probability
of Pr(yi|covariates) (denoted as z∗i ) for each subject with estimated coefficients from
this regression. We define, z∗i is transformed to be a binary variable zi (zi = 0 if z
∗
i
is less than the median and zi = 1 otherwise), and then combined with its binary si.
This leads to a new categorical variable s∗i with four categories. The missing values of
baseline covariates are imputed with simple mean imputation since the missing data
rate is very low (less than 1%).
The EM algorithm is applied to the incomplete data to obtain ML estimates for
the categorical MMNAR model. Complete case analysis is also conducted, including
only the subjects who did not drop out from the study. ML assuming MAR is also
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performed to compare with our proposed model. Table 3.5 shows estimates and
associated 95% confidence intervals for conditional means of yi given different xi
for the three methods. The estimates of the treatment effect given as absolute risk
reduction (ARR)=Pr(yi = 1|xi = 0)-Pr(yi = 1|xi = 1) are also shown in Table 3.5.
Table 3.5: Estimates of the absolute risk reduction (ARR) and the incidence of hyper-
tension under different treatment groups in TROPHY study. LCI = lower
bound of 95% confidence interval. HCI = higher bound of 95% confidence
interval.
Method Parameter Mean LCI HCI
Complete Pr(yi = 1|xi = 0) 0.73 0.69 0.78
case Pr(yi = 1|xi = 1) 0.62 0.57 0.67
analysis ARR=Pr(yi = 1|xi = 0)-Pr(yi = 1|xi = 1) 0.11 0.04 0.19
ML Pr(yi = 1|xi = 0) 0.73 0.68 0.78
assuming Pr(yi = 1|xi = 1) 0.61 0.56 0.67
MAR ARR=Pr(yi = 1|xi = 0)-Pr(yi = 1|xi = 1) 0.11 0.05 0.19
ML Pr(yi = 1|xi = 0) 0.71 0.45 0.96
assuming Pr(yi = 1|xi = 1) 0.59 0.34 0.83
MMNAR ARR=Pr(yi = 1|xi = 0)-Pr(yi = 1|xi = 1) 0.12 0.05 0.19
In Table 3.5, the incidence of hypertension for different treatment groups, Pr(yi =
1|xi = 0) and Pr(yi = 1|xi = 1) have relatively wide confidence intervals for ML
assuming MMNAR because MMNAR allows the missingness of yi to depend on yi
itself and this can potentially weaken the confidence of association between yi and xi.
However, the estimated ARR (or treatment effect) and its 95% confidence interval for
the categorical MMNAR model are 12% and (5%, 19%), which are very similar to ML
assuming MAR and the complete case analysis. Therefore the estimated treatment
effect is robust to deviations from MAR of the form implied by the MMNAR model
and we can conclude that there is a significant difference between the two groups.
Since Eq. (3.3) is more plausible than MAR for masked trials, no sensitivity analysis
is necessary.
There are several limitations related to this application. First, the transformation
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from original adverse effects variables to Si is post-hoc, and might be improved by
specifying one clearly defined side effect variable in the protocol. Second, outcomes
were recorded for every visit, and our simple analysis does not exploit the longitudinal
aspect of the study. The extension of MMNAR to longitudinal studies is under
investigation.
3.4 Discussion
The utility of masking in randomized clinical trials is widely recognized, since
it removes potential distortions from placebo effects, differential application of entry
criteria, or other behaviors that might bias treatment comparisons. However, we have
not seen discussions about the implications of masking for the treatment of missing
data in previous research. The potential for non-MAR missing data in clinical trials
is well known, but the class of MNAR models is very broad, so any reasonable way
of limiting the number of models to be considered is valuable. In masked trials, it
seems reasonable that missingness does not depend on the masked treatment, after
conditioning on side effect and outcome data. This motivates the class of MMNAR
models which we explore in this chapter. We describe MMNAR models for continuous
and categorical outcomes, and apply maximum likelihood and multiple imputation
based on these models to estimate treatment effects. Clearly many other models could
be constructed that incorporate the MMNAR assumption, depending on setting.
We note that for the MMNAR assumption to be plausible, important side effects
need to be recorded and incorporated in the analysis. Clinically unimportant side
effects do not need to be included, since to bias the treatment effect a side effect
needs to be associated with the outcome as well as the likelihood of dropping out.
Here we have considered the simple case of missing data in a univariate outcome
variable. In future work we plan to consider the class of MMNAR models for repeated
measures data with more than one missing data pattern, and to allow for missing data
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in covariates.
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3.5 Appendix
3.5.1 Proof that Eq. (3.4) follows from Eq. (3.3)
f(Xi|Yi, Si, Zi,Mi = mi) = f(Xi, Yi, Si, Zi,Mi = mi)/f(Yi, Si, Zi,Mi = mi)
= f(Mi = mi|Xi, Yi, Si, Zi)f(Xi, Yi, Si, Zi)
/[f(Mi = mi|Yi, Si, Zi)f(Yi, Si, Zi)]
= f(Xi, Yi, Si, Zi)/f(Yi, Si, Zi)
= f(Xi|Yi, Si, Zi)
3.5.2 Conditions under which the categorical MMNAR model is identi-
fied
For the categorical MMNAR model, when K > J , the number of model parame-
ters is larger than the number of cell counts, so the model is not identified. We show
that the model is identified under some regular conditions if K ≤ J . Follow (3.5),
cell probabilities are
log γjklm = α
(0) + α
(1)
j + α
(2)
k + α
(3)
l + α
(4)
m + α
(12)
jk + α
(13)
jl + α
(23)
kl
+α
(24)
km + α
(34)
lm + α
(123)
jkl + α
(234)
klm ,
where the α terms are constrained to sum to zero over any of their subscripts. Define
β
(1)
j = α
(1)
j −α(1)1 , β(12)jk = α(12)jk −α(12)1k −α(12)j1 +α(12)11 , β(123)jkl = α(123)jkl −α(123)1kl −α(123)j1l −
α
(123)
jk1 +α
(123)
j11 +α
(123)
1k1 +α
(123)
11l −α(123)111 for j = 1, . . . , J , k = 1, . . . , K, l = 1, . . . , L, and
define other β terms analogously. Therefore all terms with at least one subscript of 1
are restricted to 0. β(0) is a function of other β terms such that the cell probabilities
sum to 1.
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Define τ (0), τ
(1)
j , τ
(2)
k , τ
(3)
l , τ
(12)
jk , τ
(13)
jl , τ
(23)
kl , and τ
(123)
jkl to be the same as β
(0), β
(1)
j ,
β
(2)
k , β
(3)
l , β
(12)
jk , β
(13)
jl , β
(23)
kl , and β
(123)
jkl , respectively. Define τ
(4)
1 = exp(β
(0) + β
(4)
1 ),
τ
(24)
k1 = τ
(4)
1 exp(β
(2)
k +β
(24)
k1 ), τ
(34)
l1 = τ
(4)
1 exp(β
(34)
l1 ) and τ
(234)
kl1 = τ
(34)
l1 τ
(24)
k1 /τ
(4)
1 exp(β
(23)
kl +
β
(234)
kl1 ), for k = 2, . . . , K and l = 2, . . . , L.
First of all, τ (0), τ
(1)
j , τ
(2)
k , τ
(3)
l , τ
(12)
jk , τ
(13)
jl , τ
(23)
kl , and τ
(123)
jkl are identified since they
are corresponding to the cells that Yi is observed.
We illustrate how τ
(4)
1 and τ
(24)
k1 , k = 2, . . . , K are identified. Cell probabilities
for M = 1 and S = 1 are
log γ1111 = β
(0) + β
(4)
1 = log τ
(4)
1
log γ1k11 = β
(0) + β
(4)
1 + β
(2)
k + β
(24)
k1 = log τ
(24)
k1
log γj111 = β
(0) + β
(4)
1 + β
(1)
j = log τ
(4)
1 + τ
(1)
j
log γjk11 = β
(0) + β
(4)
1 + β
(2)
k + β
(24)
k1 + β
(1)
j + β
(12)
jk = log τ
(24)
k1 + τ
(1)
j + τ
(12)
jk ,
for j = 2, . . . , J and k = 2, . . . , K. Since Y is missing for M = 1, the observed
combined cell probabilities for M = 1 and S = 1 are
K∑
k=1
γ1k11 = τ
(4)
1 +
K∑
k=2
τ
(24)
k1
K∑
k=1
γjk11 = exp(τ
(1)
j )(τ
(4)
1 +
K∑
k=2
τ
(24)
k1 exp(τ
(12)
jk )),
for j = 2, . . . , J . Note that τ
(1)
j and τ
(12)
jk are already identified. There are J equations
and K unknown parameters with K ≤ J , so τ (4)1 , τ (24)k1 , k = 2, . . . , K are identified if
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matrix (3.6) has full rank.

1 1 . . . 1
1 exp(τ
(12)
22 ) . . . exp(τ
(12)
2K )
. . .
1 exp(τ
(12)
J2 ) . . . exp(τ
(12)
JK )

(3.6)
We then illustrate how τ
(34)
l1 , τ
(234)
kl1 , k = 2, . . . , K are identified for each l. Cell
probabilities for M = 1 and S = l are
log γ11l1 = β
(0) + β
(4)
1 + β
(3)
l + β
(34)
l1 = log τ
(34)
l1 + τ
(3)
l
log γ1kl1 = β
(0) + β
(4)
1 + β
(2)
k + β
(24)
k1 + β
(3)
l + β
(34)
l1 + β
(23)
kl = log τ
(234)
kl1 + τ
(3)
l
log γj1l1 = β
(0) + β
(4)
1 + β
(3)
l + β
(34)
l1 + β
(1)
j + β
(13)
jl = log τ
(34)
l1 + τ
(3)
l + τ
(1)
j + τ
(13)
jl
log γjkl1 = β
(0) + β
(4)
1 + β
(2)
k + β
(24)
k1 + β
(3)
l + β
(34)
l1 + β
(23)
kl + β
(1)
j + β
(13)
jl + β
(12)
jk + β
(123)
jkl
= log τ
(234)
kl1 + τ
(3)
l + τ
(1)
j + τ
(13)
jl + τ
(12)
jk + τ
(123)
jkl ,
for j = 2, . . . , J , k = 2, . . . , K, and l = 2, . . . , L. Since Y is missing for M = 1, the
observed combined cell probabilities for M = 1 and S = l are
K∑
k=1
γ1kl1 = exp(τ
(3)
l )(τ
(34)
l1 +
K∑
k=2
τ
(234)
kl1 )
K∑
k=1
γjkl1 = exp(τ
(3)
l + τ
(1)
j + τ
(13)
jl )(τ
(34)
l1 +
K∑
k=2
τ
(234)
kl1 exp(τ
(12)
jk + τ
(123)
jkl )),
for j = 2, . . . , J , k = 2, . . . , K, and l = 2, . . . , L. For each l in {2, . . . , L}, there are J
equations and K unknown parameters, so τ
(34)
l1 , τ
(234)
kl1 , k = 2, . . . , K are identified if
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matrix (3.7) has full rank.

1 1 . . . 1
1 exp(τ
(12)
22 + τ
(123)
22l ) . . . exp(τ
(12)
2K + τ
(123)
2Kl )
. . .
1 exp(τ
(12)
J2 + τ
(123)
J2l ) . . . exp(τ
(12)
JK + τ
(123)
JKl )

(3.7)
After all τ parameters are identified, β(0), β
(1)
j , β
(2)
k , β
(3)
l , β
(12)
jk , β
(13)
jl , β
(23)
kl , and
β
(123)
jkl are directly obtained. β
(4)
1 ) and β
(24)
k1 are calculated with β
(4)
1 ) = log τ
(4)
1 − β(0)
and β
(24)
k1 ) = log(τ
(24)
k1 /τ
(4)
1 )−β(2)k , for k = 2, . . . , K. β(34)l1 and β(234)kl1 are calculated with
β
(34)
l1 = log(τ
(34)
l1 /τ
(4)
1 ) and β
(234)
kl1 = log(τ
(234)
kl1 τ
(4)
1 /τ
(34)
l1 /τ
(24)
k1 )− β(23)kl , for k = 2, . . . , K.
Note that the calculated β terms may not be in the parameter space.
3.5.3 An multiple imputation procedure for the normal MMNAR models
After the ML estimates are obtained, the variance covariance matrix of the esti-
mates are calculated by multivariate delta method. Based on the estimates and their
variance covariance matrix, 20 samples of the parameter set are drawn. Then each of
the parameter set samples can be used to draw missing Yi and provide an imputed
data set. All 20 imputed data sets are analyzed separately and the 20 results are
combined with the Rubin’s combination rule (Rubin, 1987).
We apply the multiple imputation procedure because in this way, the results from
ML assuming MMNAR are more comparable with other methods.
3.5.4 Sketch proof that if the model MARSZ holds, the ML estimate for
θ1 under MMNAR is less efficient than ML under MARSZ.
The ML estimate of θ1 under MMNAR is less efficient than the ML estimate
of θ1 under MARSZ, since MARSZ is a submodel of MMNAR obtained by setting
parameters relating missingness to Y to zero. On the other hand, the ML estimate
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of θ1 under MAR is the same as the ML of θ1 under MARSZ, since both lead to
the same likelihood ignoring the mechanism. Hence ML for θ1 under MAR is more
efficient than ML under MMNAR.
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CHAPTER IV
Estimating Treatment Effect under the MMNAR
Assumption for Longitudinal Data with Dropouts
4.1 Introduction
Many methods based on MAR assumption have been proposed for longitudinal da-
ta and a detailed review can be found in Molenberghs and Kenward (2007). Generally
these methods include likelihood-based methods and weighted generalized estimating
equations (wGEE), which directly model missingness conditional on observed data.
An alternative is multiple imputation, which uses observed data to impute missing
values. Many of these methods (Hedeker and Gibbons, 1997) allowed for the miss-
ingness mechanism to be MNAR, but Molenberghs and Kenward (2007) provided a
method that can reproduce the result from any MNAR model by an MAR counter-
part. This fact shows that there is no formal data-based difference between MAR and
MNAR, so unless the MNAR model is unquestionable, a sensitivity analysis is rec-
ommended to examine whether the result is sensitive to the unverifiable assumption
(National Research Council, 2010; Molenberghs and Kenward, 2007).
Many MNAR models are proposed as a form of sensitivity analysis based on se-
lection models (Diggle and Kenward, 1994; Molenberghs et al., 2003; Mallinckrodt et
al., 2013). In this chapter, however, we focus on the pattern-mixture model frame-
57
work, under which the distinctions between different missing patterns are stated in
a transparent and meaningful way. Similar to available case missing values (ACMV)
(Molenberghs et al., 1998), the counterpart of MAR in the PMM context, MNAR as-
sumptions including complete case missing values (CCMV) (Little, 1993) which bor-
rows information from the completers, and neighboring case missing values (NCMV)
(Molenberghs et al., 2003) which borrows information from the nearest identified pat-
tern, have been developed. Ratitch et al. (2013) proposed a delta-adjusting analysis
strategy, which can explicitly control the deviation from MAR to reflect worsened
outcomes for the dropped out subjects.
In this chapter, we apply the MMNAR assumption to longitudinal data models.
Instead of specifying just one longitudinal model, we propose a flexible strategy that
can extend a preferred complete data model to a MMNAR model, after which ML
estimates are obtained and a multiple imputation procedure is used to draw inference.
The remainder of the chapter is organized as follows. In Section 4.2, we intro-
duce the notation and assumptions used in later sections. Section 4.3 describes the
procedure to extend a complete data model to incorporate the proposed MMNAR
assumption and draw inference. In Section 4.4, we conduct simulation studies that
compare our methods with alternatives. Section 4.5 presents the result from analyz-
ing the TROPHY data. A summary and some future work are discussed in Section
4.6.
4.2 Notation and Assumptions
In this section, we discuss the strategy to extend MMNAR assumption to longi-
tudinal studies. We consider a randomized clinical trial with n subjects. For the ith
subject, where i = 1, ..., n, let Xi and Zi be the treatment assignment and baseline
covariates (Zi might be a vector). Let Yij be the response of interest designed to be
measured at visit j, where j = 1, ..., T . Similarly, let Sij be the side effect measure at
58
visit j. The original intention was to have T observations of Yij for each individual,
but some of them might not be observed due to dropout. Then for subject i and visit
j, let Mij be the missing indicator for Yij, so Mij = 0, if Yij is observed, and Mij = 1,
if not. We assume that Xi, Zi, Mij, and Sij are fully observed.
The missing pattern is assumed to be monotonic. In other words, some subjects
discontinued from the study and have a number of visits with missing Yij after their
discontinuation. Let Mi denote the last visit with Yij observed, so Mi = m is equiv-
alent to Mij = 0 for j ≤ m and Mij = 1 for j > m, m = 1, ..., T . If the data is
complete for subject i, Mi = T . We define if Yij is missing from j = 1, Mi = 0.
The goal is to provide a strategy to apply MMNAR assumption to parametric
longitudinal models. If the missing mechanism is MNAR, the missing indicators are
required to be included in a joint model with other variables and we make key two
assumptions to identify the parameters in this model. The first assumption is the
proposed MMNAR assumption but in a longitudinal setting: if a subject has not
dropped out at visit j − 1, the probability that this subject drops out at visit j
is independent with the treatment assignment given all the information until visit
j including the potentially missing outcome at visit j. MMNAR assumption can
provide restrictions to identify the distribution of the missing data at the time of
dropout, but the missing data for future times require the second assumption, which
assumes that dropout may depend on the current, possibly unobserved, measurement,
but not on future measurements.
4.3 Fitting Procedure
The fitting procedure includes two steps: regression step and imputation step. In
the regression step, a parametric model is assumed and ML estimates which maximize
the likelihood with MMNAR restrictions are calculated with their variance covariance
matrix. The imputation step is a multiple imputation procedure which (a) draws D
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sets of parameters based on the ML estimates and their variance covariance matrix
obtained in the regression step; (b) draws one set of missing Yij at the time of dropout
(j = Mi + 1) for each drawn parameter set; (c) sequentially draws one set of missing
Yij for visits after dropout (j > Mi + 1) for each drawn parameter set; (d) performs
statistical analyses on each of the imputed data sets and combines the results with
Rubin’s combination rule. The details are provided as follows.
4.3.1 Step 1. Regression step.
Suppose for the complete data, the vector Yi1, ..., YiT given Xi, Zi, and Sik (k =
1, ..., T ) are
[Yi1, ..., YiT |Xi = xi, Zi = zi, Sik = sik, k = 1, ..., T, β]
∼ NT


f(xi, zi, sik, k = 1, β, j = 1)
...
f(xi, zi, sik, k = 1, ..., T, β, j = T )
 ,ΣT
 (4.1)
where NT (µ,Σ) denotes the T -dimensional multivariate normal distribution with
mean vector µ and variance-covariance matrix Σ. and Σj is

σ211 σ
2
12 ... σ
2
1j
...
σ2j1 σ
2
j2 ... σ
2
jj
 , forj = 1, ..., T
We further assume that there is no interaction between xi and other variables to
keep the form of MMNAR assumption simple. More specifically, f(xi, zi, sik, k =
1, ..., j, β, j) = βY Xjxi + f
∗(zi, sik, k = 1, ..., j, β, j).
We introduce the missing indicator within the pattern-mixture model (PMM)
framework, under which, subjects are stratified according to their missingness pat-
terns. We assume a logistic form for the probability of subject i dropping out at visit
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j given all the observed information. More specifically, for j = 1, ..., T , we assume
logit(Pr(Mij = 1|Mi(j−1) = 0, Xi = xi, Zi = zi, Sik = sik, Yil = yil,
k = 1, ..., j, l = 1, ..., j − 1))
= h(xi, zi, sik, yil, k = 1, ..., j, l = 1, ..., j − 1, β, j). (4.2)
For simplicity consideration, we assume there is no interaction between xi and oth-
er variables. More specifically, h(xi, zi, sik, yil, k = 1, ..., j, l = 1, ..., j − 1, β, j) =
βMXjxi + h
∗(zi, sik, yil, k = 1, ..., j, l = 1, ..., j − 1, β, j).
Under the missing pattern Mi = m, m = 0, ..., T − 1, we add a ‘dropping effect’
βYM(m+1) to the mean of Yi(m+1) and the vector Yi1, ..., Yi(m+1) given Xi, Zi, and Sik
(k = 1, ...,m+ 1) are
[Yi1, ..., Yi(m+1)|Xi = xi, Zi = zi,Mi = m,Sik = sik, k = 1, ...,m+ 1] (4.3)
∼ Nm+1


f(xi, zi, sik, k = 1, β, j = 1)
...
f(xi, zi, sik, k = 1, ...,m, β, j = m)
f(xi, zi, sik, k = 1, ...,m+ 1, β, j = m+ 1) + βYM(m+1)

,Σm+1

.
In total of T parameters, βYM1, ..., βYMT , quantify the difference between missing
patterns, but they cannot be identified for the unrestricted model. MMNAR assump-
tion implies that probability of Mij = 1 does not depend on Xi given all the observed
information including the potentially unobserved Yij. So ∀j ∈ {1, ..., T}
Pr(Mij = 1|Mi(j−1) = 0, Xi, Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j, β)
= Pr(Mij = 1|Mi(j−1) = 0, Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j, β). (4.4)
The model specified in Eq. (4.2) and Eq. (4.3) implied that the left side of Eq.
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(4.4) follows a logistic form
logit(Pr(Mij = 1|Mi(j−1) = 0, Xi = xi, Zi = zi, Sik = sik, Yil = yil,
k = 1, ..., j, l = 1, ..., j, β))
= αMjXxi + g(zi, sik, yil, k = 1, ..., j, l = 1, ..., j, β, j), (4.5)
where αMjX and g(·) are known functions of β, f(·), and h(·) (Details are in Ap-
pendix 4.7.1). Eq. (4.4) is equivalent to αMjX = 0, j = 1, ..., T , which provides T
restrictions. Since there are T unidentified parameters from the unrestricted mod-
el and T restrictions are implied from the MMNAR assumption, the model is just
identified. ML estimates and their variance covariance matrix can be obtained by
maximizing the likelihood with MMNAR restrictions and applying the delta method.
Detailed estimation procedure is described in Appendix 4.7.2 for the specific example
in Section 4.4.
Note that when Mi = m, only Yij up to j = m + 1 are defined in Eq. (4.3).
Distribution of Yij|Mi(j−1) = 1 is restricted with the second key assumption: dropout
may depend on the current, possibly unobserved, measurement, but not on future
measurements. Kenward et al. (2003) showed that this assumption is equivalent to a
non-future dependent missing value restriction (NFMV) as follows:
∀j > m+ 1 : d(Yij|Yi1, ..., Yi(j−1),Mi = m) = d(Yij|Yi1, ..., Yi(j−1),Mi ≥ j − 1), (4.6)
where d(·) denotes the probability density function. Eq. (4.6) becomes the following
restriction with side effects and covariates included.
∀j > m+ 1 : d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = m)
= d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1) (4.7)
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The right side of Eq. (4.7) is determined with the model in Eq. (4.3) and Eq. (4.2)
because it only involves Yij up to j = Mi + 1. Then distribution of Yij|Mi(j−1) = 1 is
fully defined by β, f(·), and h(·).
Although patients may discontinue the treatment assigned after dropout, this
issue is not in the scope of this chapter and we focus on the missing outcome that
would have been observed if the patient does not drop out and continues to receive
the assigned treatment.
4.3.2 Step 2. Imputation step.
After the ML estimates and their variance covariance matrix are obtained, D
samples of the parameter set are drawn. For each sample of the parameters, for
subject i with Mi = m < T , Yi(m+1) is drawn based on conditional distribution of
Yi(m+1) given Xi, Zi, Sik, (k = 1, ...,m+1), and Yil (l = 1, ...,m) (Details in Appendix
4.7.4). Then Yij for j = m+ 2, ..., T are sequentially drawn based on the conditional
distribution of Yij given Xi, Zi, Sik, (k = 1, ..., j), and Yil (l = 1, ..., j − 1) (Details in
Appendix 4.7.5).
After D imputed data sets are generated, the desired statistical analyses can be
performed on each of the imputed data sets and the results are combined with Rubin’s
combination rule.
4.4 Simulation studies
In this section we investigate the behaviour of the proposed likelihood analysis
through simulation studies. The sample size is set to 400 to reflect a typical applied
scenario in clinical trials. The sample has two groups, with 200 subjects assigned to
each group, and T=3 equally spaced repeated measurements. One baseline covariate
Zi is included and independent with the treatment assignment Xi. For j = 1, ..., T ,
Sij is assumed to only depend on Xi, Zi, and Si(j−1); Mij|Mi(j−1) = 0 is assumed to
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only depend on Xi, Zi, Sij, and Si(j−1); Yij|Mi(j−1) = 0 is assumed to only depend
on Xi, Zi, Sij, and Mij; σij is assumed to be σ
2ρ|i−j|, where ρ0 = 1. Parameters are
specified in Table 4.1. Note for subject i with Mi = m, Yi1, ..., Yi(m+1) are generated
with (4.3) directly, and Yi(m+1), ..., YiT are generated with the NFMV restriction.
Table 4.1: Parameters used to generate longitudinal models
Scenario 5: the longitudinal model when MMNAR is true.
Variable Parameters
Zi Zi ∼ N(1, 1)
Sij|Xi, Zi, Si(j−1) logit(Sij = 1|xi, zi, si(j−1)) = −1 + 0.15xi + 0.3zi + 0.1si(j−1)
Mij|Mi(j−1) = 0 h(xi, zi, sik, yil, β, j)=−2− xi + 0.5zi + sij + 0.5si(j−1)
Yij|Mi(j−1) = 0 f(xi, zi, sik, β, j)=−1 + xi + 0.5zi + 0.2sij
Yij|Mi(j−1) = 0 {βYM1, βYM2, βYM3} = {−1,−1.4,−1.6}
Yij|Mi(j−1) = 0 {σ2, ρ1, ρ2} = {1, 0.4, 0.3}
Scenario 6: the longitudinal model when both MMNAR and MAR are true.
Variable Parameters
Zi Zi ∼ N(1, 1)
Sij|Xi, Zi, Si(j−1) logit(Sij = 1|xi, zi, si(j−1)) = −1 + 0.15xi + 0.3zi + 0.1si(j−1)
Mij|Mi(j−1) = 0 h(xi, zi, sik, yil, β, j)=−2 + 0.5zi + sij + 0.5si(j−1)
Yij|Mi(j−1) = 0 f(xi, zi, sik, β, j)=−1 + xi + 0.5zi + 0.2sij
Yij|Mi(j−1) = 0 {βYM1, βYM2, βYM3} = {0, 0, 0}
Yij|Mi(j−1) = 0 {σ2, ρ1, ρ2} = {1, 0.4, 0.3}
In scenario 5, MMNAR is true but MAR is violated because βYM1, βYM2, βYM3
are nonzero. This scenario leads to the missing rate of Pr(Mi = 0) = 26.3%, Pr(Mi =
1) = 20.5%, and Pr(Mi = 2) = 14.0%. The mean of last measurement with Xi = 0
(E(Yi3|Xi = 0), considered to be the intercept) and the difference between two groups
(E(Yi3|Xi = 1)−E(Yi3|Xi = 0), considered to be the treatment effect) are of interest.
1000 sets of data are generated and for each set, complete case analysis, ML assuming
MAR, ML assuming MMNAR, and before deletion data analysis are applied (details
in Appendix 4.7.3). For each method, the empirical mean and MSE of the estimates,
and the coverage proportion (CP) of the 95% confidence interval (CI) are presented
in Table 4.2. The 95% CI is calculated with a normal approximation. The true
values are also provided for comparison. In Table 4.2, treatment effect from both
64
Table 4.2: Finite sample properties of four methods based upon 1,000 simulations of
a clinical trial with 400 patients. In scenario 5, MMNAR is true and in
scenario 6, both MMNAR and MAR are true. MSE = 103 × mean squared
error. CP = 102 × coverage proportion for 95% confidence interval. CP*
is based on Bootstrap methods.
Method Parameter True Mean MSE CP CP*
Scenario 5: the longitudinal model when MMNAR is true.
Before deletion E(Yi3|Xi = 0) -0.46 -0.45 11 94.4 NA
data analysis E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.27 1.27 21 94.9 NA
Complete case E(Yi3|Xi = 0) -0.46 -0.35 36 87.8 NA
analysis E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.27 1.20 43 93.6 NA
ML assuming E(Yi3|Xi = 0) -0.46 0.07 290 0.3 0.4
MAR E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.27 1.01 89 65.0 56.9
ML assuming E(Yi3|Xi = 0) -0.46 -0.47 28 97.1 95.8
MMNAR E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.27 1.29 28 96.7 94.3
Scenario 6: the longitudinal model when both MMNAR and MAR are true.
Before deletion E(Yi3|Xi = 0) 0.07 0.07 10 94.3 NA
data analysis E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.01 1.01 21 95.0 NA
Complete case E(Yi3|Xi = 0) 0.07 -0.35 199 20.0 NA
analysis E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.01 1.00 49 94.9 NA
ML assuming E(Yi3|Xi = 0) 0.07 0.07 11 97.5 94.1
MAR E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.01 1.01 22 97.7 95.0
ML assuming E(Yi3|Xi = 0) 0.07 0.06 18 96.9 95.3
MMNAR E(Yi3|Xi = 1)− E(Yi3|Xi = 0) 1.01 1.02 22 97.9 95.3
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complete case analysis and ML assuming MAR are biased, showing the potential for
bias when the missing data mechanism is MNAR. Our proposed method is essentially
unbiased with small MSE, but the coverage proportions are larger than 95%. This
is because when the imputation model (4.3) is correct and more complex than the
analysis model which does not make any distribution assumption, the result from the
multiple imputation combination rule may overestimate the variance (Meng, 1994).
CP* are based on the variance estimated from bootstrap methods, and have coverage
proportions close to 95%. Since before deletion analysis and CC analysis do not
involve the MI procedure, bootstrap is not necessary.
In scenario 6, both MMNAR and MAR are true because all of βMXj , βYM1, βYM2,
and βYM3 are 0. The parameters for generating the samples are specified in Table
4.1. They lead to the missing rate of Pr(Mi = 0) = 19.3%, Pr(Mi = 1) = 16.4%, and
Pr(Mi = 2) = 12.1%. True values of E(Yi3|Xi = 0) and E(Yi3|Xi = 1)− E(Yi3|Xi =
0), along with the empirical mean and MSE of the estimates, CP and CP* of the
95% CI for each method are presented in Table 4.2. Both ML assuming MAR and
ML assuming MMNAR are unbiased with small MSE, and CP* is close to 95%.
Note that MSE of ML assuming MAR and ML assuming MMNAR for E(Yi3|Xi =
1)− E(Yi3|Xi = 0) are almost the same as MSE of before deletion analysis, which is
because the information of model assumptions in (4.3) is used in the imputation steps
of ML assuming MAR and ML assuming MMNAR, but the before deletion analysis
does not make such assumptions.
4.5 Application
The data for the TROPHY study (Julius et al., 2006) consisted of 772 patients who
were randomized to placebo group (381) and candesartan group (391). Let xi be the
binary treatment indicator with xi = 0 denoting the placebo arm and xi = 1 denoting
the candesartan arm. Let zi be the baseline covariates collected at the beginning of
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the study. After the treatment was initiated, 9 visits were scheduled at month 1, 3,
6, and every 3 months until month 24. Let yij be the systolic blood pressures (SBP)
measured at visit j for ith subject, j = 1, ..., 9. One reason to cause yij missing was
development of hypertension. Development of hypertension was defined as the first
appearance of one of the following outcomes: systolic pressure of 140 mm Hg or high-
er or diastolic pressure of 90 mm Hg or higher, for any three visits; systolic pressure
of 160 mm Hg or higher or diastolic pressure of 100 mm Hg or higher for any visit;
initiation of pharmacologic treatment; or systolic pressure of 140 mm Hg or higher
or diastolic pressure of 90 mm Hg or higher at the visit at month 48. Once a patient
was diagnosed of hypertension, a rescue therapy was initiated and the blood pressures
recorded were no longer relevant. Among the 772 patients, 198 (47 in candesartan
group) had missing values of yij because of developing hypertension. Since develop-
ment of hypertension was fully determined by the observed information, the missing
mechanism was MAR. Let ∆i = 1 denote that subject i developed hypertension and
let ∆i = 0 denote that subject i completed the study. Let hi denote the specific visit
that hypertension was diagnosed. If ∆i = 1, yihi was the last measurement of SBP.
Our particular interest here is the average last SBP before hypertension or the
end of study for different treatment groups, or Exi = E(yihi ∗ I(∆i = 1) +yi9 ∗ I(∆i =
0) | xi), where I(·) is the indicator function. Note that missing values of yij for j > hi
are not related to our parameter of interest, so from this point, missing yij caused
by development of hypertension (∆i = 1) are not considered as missing data to avoid
confusion.
The other reason to cause yij missing was dropout, which is denoted by ∆i =
2. Among those 772 patients, 84 (37 in candesartan group) dropped out from the
study before development of hypertension. Let mi denote the visit in which the last
measurement of SBP was observed before dropout. Let mij be the missing data
indicator for yij with mij = 1 denoting subject i dropping out before visit j. The
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missing pattern is monotone so for subject i with ∆i = 2, mi = r ⇔ mij = 0 for
j = 1, ..., r and mij = 1 for j = r + 1, ..., 9. If ∆i 6= 2, mij = 0 for j = 1, ..., 9.
Since blood pressures could be measured at home, patients might drop out be-
cause of lack of efficacy and therefore MAR is questionable. The proposed MMNAR
model in Section 4.4 is applied except the true parameters are unknown. One naive
longitudinal analysis was performed to determine the baseline covariates to be in-
cluded in the MMNAR model. Race, sex, BMI, age, creat, and baseline SBP were
significantly related to outcomes and therefore included in zi. Time trend for SBP
was not observed and excluded.
Following the fitting procedure described above, ML estimates are obtained and
imputed data sets are generated, but after all the missing values of yij are imputed, an
extra imputation step is required to create the possibility to diagnose hypertension. In
this step, we assume the probability to diagnose hypertension only depends on the last
observed SBP by a logistic form: logit(Pr(hi(j+1) = 1|yij, hij = 0)) = βH0 + βHY yij,
j = 1, ..., 8, where hij is the hypertension indicator, hi = w ⇔ hij = 0 for j = 1, ..., w
and hij = 1 for j = w+ 1, ..., 9. The ML estimates of βH0 and βHY and their variance
covariance matrix are obtained by fitting a logistic regression with all observed yij.
Then for each imputed data set, following the imputation step, one set of βH0 and
βHY is randomly drawn to generate hij sequentially until hij = 1 or j = 9.
The analysis for complete data does not make any distribution assumption. Eˆ0 and
Eˆ1 (estimates of E0 and E1), and Vˆ (E0) and Vˆ (E1) (their variances) are the empirical
means and variances for the two treatment groups. Estimate of the treatment effect
E1 − E0 and its variance are simply Eˆ1 − Eˆ0 and Vˆ (E0) + Vˆ (E1). The results from
complete case analysis, ML assuming MAR, and ML assuming MMNAR are presented
in Table 4.3.
The estimated treatment effect from ML assuming MMNAR is slightly larger
than the one from ML assuming MAR. It indicates that allowing the missingness of
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Table 4.3: Estimates of the systolic blood pressure (SBP) at endpoint under different
treatment groups in TROPHY study. LCI = lower bound of 95% confi-
dence interval. HCI = higher bound of 95% confidence interval. Width =
width of 95% confidence interval.
Method Parameter Mean LCI HCI Width
Complete case E0 129.0 127.8 130.2 2.4
analysis E1-E0 -6.7 -8.4 -5.1 3.3
ML assuming E0 130.8 129.5 132.0 2.5
MAR E1-E0 -7.9 -9.6 -6.2 3.5
ML assuming E0 132.4 130.4 134.5 4.2
MMNAR E1-E0 -8.8 -10.7 -6.9 3.9
yij to depend on yij itself may alter the treatment effect. This also confirms that
the treatment effect to decrease blood pressures is robust to deviation from MAR
assumption. E0 has relatively wide confidence interval for ML assuming MMNAR,
but the width of E1−E0 confidence interval for ML assuming MMNAR is very similar
to the one for ML assuming MAR. This observation is very similar to the pattern in
previous simulation studies.
4.6 Discussion
In this section we describe MMNAR models for repeated measure data. Since
the longitudinal data models are flexible, rather than specifying one MMNAR model,
we provide the strategy to extend a complete data model to a MMNAR model and
estimate parameters of interest by applying maximum likelihood and multiple impu-
tation. Since the imputation model may be more complex than the analysis model
for the complete data, the variance estimates from the multiple imputation combi-
nation rule may be overestimated and a bootstrap method is suggested to correct
the variance estimation. Applying longitudinal MMNAR models to real data is also
illustrated with TROPHY study, and ML assuming MMNAR provides a result that
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is slightly different from ML assuming MAR. This indicates that MAR may be mildly
violated.
In the TROPHY study application, side effect variables are summarized to one
single variable to be included in the model, and the way to summarize those side
effect data can be improved for the future work, for example, by using a propensity
score which models the propensity to drop out.
In the future work, we will also extend the MMNAR assumption to other paramet-
ric or semiparametric regression models, like generalized linear models and survival
analysis models. For those models, restrictions implied by the MMNAR assumption
may not be as well defined as the logistic form illustrated above and how to apply
the MMNAR assumption properly requires further investigation.
We already considered the case when the outcome is missing, and the MMNAR
assumption can be useful for missing covariates when MAR is questionable. If the
missing probability does not depend on outcomes, the estimates based on CC analysis
may be valid, but efficiency loss is often unavoidable. More sophisticated methods
such as subsample ignorable likelihood (SSIL) method (Little and Zhang, 2011) often
assume MAR, but they are robust to slight violation of ignorability. The compari-
son between ML assuming MMNAR and other methods for different settings are of
interest.
In the longitudinal MMNAR model, we assume the missing pattern is monotone
and adopt a sequential MI procedure for the inference. For future work, it is interest-
ing to see how to apply chained equation MI methods to the longitudinal data with
arbitrary missing pattern. This can greatly simplify the application of the method
by using existing software include IVEware (Raghunathan et al., 2001) and MICE
(VanBuuren and Groothuis-Oudshoorn, 2011).
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4.7 Appendix
4.7.1 Coefficients in Eq. (4.5)
logit(Pr(Mij = 1|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β)) (4.8)
= log
Pr(Mij = 1|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β)
Pr(Mij = 0|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β)
= log
Pr(Mij = 1, Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β)
Pr(Mij = 0, Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β)
= log
d(Yij|Mij = 1, Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j − 1,Mi(j−1) = 0, β)
d(Yij|Mij = 0, Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j − 1,Mi(j−1) = 0, β)(4.9)
+ log
Pr(Mij = 1|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j − 1,Mi(j−1) = 0, β)
Pr(Mij = 0|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j − 1,Mi(j−1) = 0, β)(4.10)
Expression (4.10) is βMXjXi + h
∗(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j) based
on Eq. (4.2). Eq. (4.3) implies that [Yij|Mij = 0, Xi, Zi, Sik, k = 1, ..., j, Yil, l =
1, ..., j− 1,Mi(j−1) = 0, β] follows a normal distribution with mean of µj and variance
of σ2j . µj is
f(Xi, Zi, Sik, k = 1, ..., j, β, j)
+Σ′1(j−1)Σ
−1
j−1

Yi1 − f(Xi, Zi, Sik, k = 1, β, 1)
...
Yi(j−1) − f(Xi, Zi, Sik, k = 1, ..., j − 1, β, j − 1)
 (4.11)
= f ∗(Zi, Sik, k = 1, ..., j, β, j)
+Σ′1(j−1)Σ
−1
j−1

Yi1 − f ∗(Zi, Sik, k = 1, β, 1)
...
Yi(j−1) − f ∗(Zi, Sik, k = 1, ..., j − 1, β, j − 1)

+ [βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]Xi
= µ∗j + [βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]Xi,
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where Σ1(j−1) is the vector (σ211, ..., σ
2
1(j−1)) and µ
∗
j does not depend on Xi. Variance
σ2j has the form of σ
2
jj − Σ′1(j−1)Σ−1j−1Σ1(j−1). Similarly, [Yij|Mij = 1, Xi, Zi, Sik, k =
1, ..., j, Yil, l = 1, ..., j − 1,Mi(j−1) = 0, β] follows a normal distribution with mean of
µj + βYMj and variance of σ
2
j . Plug µj, σ
2
j , and βYMj in (4.9), we get
−1/2 · log(2piσ2j )−
(Yij − µj − βYMj)2
2σ2j
− (−1/2 · log(2piσ2j )−1/2 −
(Yij − µj)2
2σ2j
)
= (2Yij − 2µj − βYMj)βYMj/(2σ2j )
= (2Yij − 2µ∗j − βYMj)βYMj/(2σ2j )
−[βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]XiβYMj/σ2j
Plug in the expressions of (4.9) and (4.10), we have
logit(Pr(Mij = 1|Xi, Zi, Sik, k = 1, ..., j, Yil, l = 1, ..., j,Mi(j−1) = 0, β))
= (2Yij − 2µ∗j − βYMj)βYMj/(2σ2j )
−[βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]XiβYMj/σ2j
+βMXjXi + h
∗(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j)
= {βMXj − [βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]βYMj/σ2j}Xi
+(2Yij − 2µ∗j − βYMj)βYMj/(2σ2j )
+h∗(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j)
αMjX in Eq. (4.5) is βMXj − [βY Xj − Σ′1(j−1)Σ−1j−1(βY X1 , ..., βY Xj−1)′]βYMj/σ2j .
4.7.2 Obtain ML estimates for MMNAR models
Since there are T unidentified parameters from the unrestricted model and T
restrictions are implied from the MMNAR assumption, the model is just identified.
The loglikelihood is maximized by (a) calculating the ML estimates of parameters
in h(·) with Mij given Xi, Zi, Sij, and Si(j−1) for all {i, j} that satisfy Mi(j−1) = 0;
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(b) calculating the ML estimates of parameters in f(·) with Yi1, ..., Yim given Xi,
Zi, Si1, ..., Sim, for subjects with Mi = m; and (c) calculating the estimated value
of βYM1, ..., βYM3 with restrictions αMjX = 0, j = 1, 2, 3, implied by the MMNAR
assumption (forms of αMjX in Appendix 4.7.1). Variance estimates in (a) and (b)
are computed from the inverse of the information matrix and delta method is used
to calculate the variance estimates in (c).
4.7.3 Estimation procedures for different methods
Let βˆintercept and Vˆintercept be the estimate of E(Yi3|Xi = 0) and the associated
variance estimate. Let βˆtrt.effect and Vˆtrt.effect denote the estimate of E(Yi3|Xi = 1) −
E(Yi3|Xi = 0) and the associated variance estimate.
We first introduce the estimation method for complete data, in which no distribu-
tion assumption is made. We use the empirical mean and variance of Yi3 for treatment
group Xi to estimate E(Yi3|Xi) and the associated variance, which are denoted by
βˆXi and VˆXi . Then we have βˆintercept = βˆ0, Vˆintercept = Vˆ0, βˆtrt.effect = βˆ1 − βˆ0, and
Vˆtrt.effect = Vˆ1 + Vˆ0.
Complete case analysis and before deletion data analysis are direct application of
the estimation method for complete data. Note that this method is also the analysis
performed after imputed data sets are generated in ML assuming MMNAR or ML
assuming MAR. Estimation procedure for ML assuming MMNAR is provided in Sec-
tion 4.3. ML assuming MAR has a very similar procedure, which sets estimates and
the variances of βYM1, ..., βYM3 to 0 instead of calculating them with the restrictions
(step (c) in Appendix 4.7.2).
4.7.4 Imputing Yi(m+1) for Mi = m < T
Since Mi = m ⇔ Mim = 0 & Mi(m+1)=1, conditional distribution of Yi(m+1) given
Xi, Zi, Sik, (k = 1, ...,m+ 1), and Yil (l = 1, ...,m) is µj + βYMj, where µj is given in
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(4.11).
4.7.5 Imputing Yij for j = m+ 2, ..., T , Mi = m < T − 1
Because Eq. (4.7), for Mi = m < T − 1, ∀j > m+ 1,
d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = m)
= d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1)
=
T∑
l=j−1
d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = l)
·Pr(Mi = l|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1)
=
T∑
l=j−2
d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = l)
·Pr(Mi = l|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1)
+ d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = j − 1)
·Pr(Mi = j − 1|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1)
Note that since [Yi1, ..., Yi(j−1), Yij|Si1, ..., Sij, Xi, Zi,Mi = l] is the same for all l ≥
j − 2, [Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = l] is the same for all l ≥ j − 2. We
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have
d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = m)
=
T∑
l=j−2
Pr(Mi = l|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi ≥ j − 1)
·d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi = T )
+ d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mij = 1,Mi(j−1) = 0)
·Pr(Mij = 1|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi(j−1) = 0)
= d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mij = 0,Mi(j−1) = 0)
·Pr(Mij = 0|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi(j−1) = 0)
+ d(Yij|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mij = 1,Mi(j−1) = 0)
·Pr(Mij = 1|Yi1, ..., Yi(j−1), Si1, ..., Sij, Xi, Zi,Mi(j−1) = 0)
= φ(Yij, µj, σ
2
j )
1
exp{1 + h(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j)}
+φ(Yij, µj + βYMj, σ
2
j )
exp{1 + h(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j)}
1 + exp{1 + h(Zi, Sik, Yil, k = 1, ..., j, l = 1, ..., j − 1, β, j)} ,
where φ(x, µ, σ2) denotes the normal density function with mean µ and variance σ2.
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CHAPTER V
Conclusions and Future Work
We consider missing data problems in randomized controlled trials. Noncom-
pliance with the assigned treatment and missing outcomes can undermine the ran-
domization, which is a key feature for drawing valid statistical inferences for the
comparison between treatments. For the noncompliance issue, we focus on the treat-
ment switching for phase III clinical trials in oncology and propose a likelihood-based
method and a latent event time method. The proposed methods outperform exist-
ing methods in the simulation studies conducted. For the missing outcomes issue,
a specific MNAR assumption is proposed and applied to a variety of models. The
TROPHY study provides a real data application.
In Chapter 2, we propose a new parametric method to address the treatment arm
switching issue. This method evaluates the individual benefit of switching based on
observed progression time so the switching effect differs among patients. We also
propose a latent event time method based on the iterative parameter estimation
procedure. This method is more robust to violations of the distribution assumptions
in the parametric method.
Via simulations, we show that our proposed methods are unbiased with small
MSEs, but the existing methods, ITT analysis, PP analysis, Cox PH model with time-
varying covariate, and the IPE procedure may be biased when treatment switching
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depends on the subjects’ progression time. We analyze the reasons for bias, in the case
of the IPE procedure we suggest that bias arises because the selection of switching
can change the causal effect.
For the inference to be valid, the decision of treatment switching must not depend
on the future information (for example, investigator’s judgement for the event time)
conditional on the observed information at progression time. This assumption is
unverifiable from the data being analyzed and questionable in practice, so we recom-
mend weakening it by collecting variables associated with both treatment switching
and the future event time.
Our key assumption that the treatment effect is the same both before and after
disease progression, that is DT i ≡ DGi ≡ DTGi using the notation of Chapter 2,
may appear strong but is intuitive. It provides an idea to understand the association
between the causal effect of treatment with survival both before progression and
after progression and leads to our proposed adjustments for treatment arm switching.
For the future work, the assumption may be relaxed by assuming DGi and DT i are
positively correlated instead of equal to each other. Note that although the correlation
between DGi and DT i (denoted as ρTG) may be unidentifiable, the robust approaches
proposed in Section 2.5 with ρ1 replaced by ρ1ρTG could be applied, although a
sensitivity analysis for the assumed value of ρ1ρTG would still be required.
A potential approach to recensoring for our latent event time approach is under
investigation. We will also apply the proposed idea to semiparametric methods, such
as a Cox PH model, in which the hazard ratio between treatment groups before
progression is assumed to be equal to the hazard ratio after progression and the
switching effect can be quantified individually.
In Chapter 3, we propose the masked missing not at random (MMNAR) assump-
tion for masked clinical trials, where missingness does not depend on the masked
treatment, after conditioning on side effect and outcome data. The MMNAR as-
77
sumption can be considered as an alternative to MAR or a way to limit the number
of possible MNAR models for the sensitivity analysis.
We describe MMNAR models for continuous and categorical outcomes, and apply
maximum likelihood and multiple imputation based on these models to estimate
treatment effects. Simulation studies show that when MAR is violated, assuming
MAR can lead to severe bias. Therefore if the estimates are substantially different,
which indicates a deviation from MAR, we might prefer the estimates from MMNAR
because the mechanism is more plausible but if the estimates based on MMNAR
and MAR are similar, MAR analysis might be preferred for efficiency considerations.
However, the mean squared errors of treatment effect estimates for MMNAR are very
similar to those for MAR in almost all the simulations conducted. How to generalize
this observation with theoretical approaches is still under investigation.
Clinically unimportant side effects do not need to be included because to bias
the treatment effect a side effect needs to be associated with the outcome as well as
the likelihood of dropping out. However, with extensive data on side effects methods
for summarizing them are of interest, and better methods than those used in the
TROPHY study application is a topic for future research. One potential approach is
to use a propensity score that models the propensity to drop out.
We will also extend the MMNAR assumption to other parametric or semipara-
metric regression models, like generalized linear models and survival analysis models.
In those models, the MMNAR assumption may imply some restrictions that are not
in a well recognized form such as logistic. How to utilize those restrictions to identify
MMNAR models requires further investigation.
In Chapter 4, we extend our proposed MMNAR assumption to repeated measure
data. Instead of specifying some MMNAR model examples in Chapter 3, we provide
the strategy to extend a complete data model to a MMNAR model and estimate
parameters of interest by applying maximum likelihood and multiple imputation.
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We notice the variance estimates from the multiple imputation combination rule
may be overestimated because the difference between imputation model and analysis
model, and the bootstrap approach can provide a valid estimate of the variance.
Finite sample properties of the proposed method are examined by simulation studies,
the result shows the same pattern as observed in the univariate outcome variable
simulations in Chapter 3. When MAR is violated, The method assuming MAR can
be biased when MAR is violated but it is preferred when MAR is correct. The
application to TROPHY study shows a slightly difference between assuming MAR
and assuming MMNAR.
We have considered the simple case when the missing pattern is monotone. How-
ever, for other missing patterns, or situations with missing covariates, the sequential
MI procedure introduced cannot be applied and other approaches such as chained
equation MI methods need to be developed. It would also be worthwhile to develop
weighting methods for a monotone pattern with masked data, and compare them
with our likelihood based methods.
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